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Abstract
Background: Surgical intervention for breast malignancy is the treatment of choice for the breast
cancer patient population. Extensive research has established the correlation between the mode
of anesthetic delivery and breast cancer recurrence and metastasis in patients undergoing surgical
intervention for breast cancer. Researchers have identified the implications of volatile anesthetic
agents (VAA), or inhalational agents, on the suppression of the immune response throughout the
perioperative period; thus, cultivating an environment that is ideal for cancer cell proliferation,
migration, and eventual metastasis via systemic circulation. Although the standardization of the
anesthetic management for this patient population has not been declared, total intravenous
anesthesia (TIVA) has been identified as the optimal anesthetic method to reduce the risk of
breast cancer recurrence and metastasis in patients undergoing breast surgery, due to the
immunologic protectant effects proffered by the drugs utilized in TIVA anesthetic
administration.
Methods: PubMed, Google Scholar, and the Cumulative Index of Nursing and Allied Health
Literature (CINAHL) search engines were accessed via the Florida International University
(FIU) library database to compose a comprehensive search for peer-reviewed research studies
within the last 10 years that examined the effects of VAA or TIVA anesthetic on breast cancer
recurrence and metastasis in patients undergoing surgical intervention for breast cancer.
Results: Eight high-level research articles were selected for appraisal and inclusion of this
review due to novelty and relevance. The articles included in this review evaluate the long-term
effects of VAA or TIVA anesthetic delivery on breast cancer recurrence and metastasis in the
breast cancer patient surgical population and identify the existing research-to-practice gap that
must be addressed in the anesthesia community to yield the best possible outcomes for the
aforementioned target population.
Conclusion: Current evidence-based research has illuminated the impactful role that anesthesia
providers may have on the long-term outcomes of patients with breast malignancy presenting for
surgical intervention via the selection of a TIVA-based anesthetic approach. It is anticipated that
the implementation of a QI project will enhance the anesthesia providers’ capacity to improve
the quality of life and reduce the risk of life-altering implications with the selection of their
anesthetic approach in breast cancer patients.

Keywords: Inhalational Agents, Volatile Anesthetic Agents, Breast Cancer Surgery, Breast Cancer
Recurrence, Breast Cancer Metastasis, Total Intravenous Anesthesia
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I. Introduction
Problem Identification
Breast malignancy is one of the most prevalent and aggressive forms of cancer that
continues to usurp the lives of a vast number of women in the United States (US). Documented
as the second most common form of cancer and leading cause of cancer-related mortality among
women in the US, up to 284,200 new cases of breast cancer diagnoses and approximately 44,000
breast cancer associated deaths occur in the US each year.1-2 Metastasis is documented as the
primary culprit for mortality in the breast cancer patient population with alarming statistics as
high as 25%.3-6 As breast malignancy diagnoses persist in a steady state, the number of women
undergoing surgical resection of breast malignancies to manage their diagnosis have paralleled as
the recommended treatment; thus, presenting anesthesia providers with the dilemma of selecting
an anesthetic technique that can maximize the resistance to breast cancer cell proliferation.
Current research suggests that the perioperative anesthetic technique of a patient
undergoing breast cancer surgery may be associated with cancer recurrence and metastasis
through varying mechanisms that may potentiate or mitigate the spread of cancerous cells,
particularly the administration of volatile anesthetic agents (VAA) compared with total
intravenous anesthesia (TIVA), respectively.3, 7-13 Although many high-level studies have
demonstrated the direct and indirect benefits of utilizing TIVA to reduce the prevalence of
cancer recurrence and metastasis in patients who underwent surgical interventions for breast
malignancy, the standardization of a TIVA-based anesthetic approach for the aforementioned
patient population to eradicate the risk of recurrence has not been established.3, 7-13 As on-going
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comprehensive research continues to solidify the existing evidence that connects TIVA
technique to a reduction in cancer recurrence in breast cancer patients to pave the way for a gold
standard of anesthetic care, it is the responsibility of anesthesia providers to keep abreast modern
clinical findings and tailor the anesthetic approach to optimize this patient population and
provide a favorable long-term outcome based on available evidence.14
Implementation of a TIVA-based anesthetic technique in the breast cancer patient
population is pivotal to anesthetic practice, as the choice of anesthetic may determine the
difference between a subsequent cancer diagnosis or a cancer-free life for breast cancer survivors
post-surgical intervention.7 The aim of this Quality Improvement project is to enhance the
knowledge of anesthesia providers regarding the correlation between TIVA and reduced breast
cancer recurrence and metastasis compared with VAA via a comprehensive educational module
to initiate a paradigm shift in the anesthetic management of surgical patients with breast cancer
presenting for surgery.
Background
Surgical intervention is considered a curative method for breast cancer; however, it is
well-documented that resection of malignant tissue during breast surgery is associated with
systemic proinflammatory alterations that support cancer cell proliferation, a precursor for
recurrence and metastasis.7,9 Additional research has linked various anesthetic agents and
techniques to the promotion or prevention of the various immunologic and inflammatory
systemic responses to surgical stress that are responsible for cancer metastasis.3-7 Understanding
the mechanisms by which cancer cells thrive, as well as, the body’s natural immunologic defense
is a critical component to grasping the severity of anesthesia technique in relation to long-term
outcomes in patients presenting for breast cancer surgery.
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Similar to healthy cell tissue, malignant cells rely on nutrients from blood supply that is
provided from adjacent vasculature.6 Increased nutrients requirements results in the activation of
angiogenesis by cancer cells via stimulation of vascular endothelial growth factor (VEGF) and
prostaglandin E2 (PGE2) to create additional circulation pathways; thus, an increase in perfusion
to the malignant tissue.6,9 Malignant cell-mediated angiogenesis coupled with the embolization
of upregulated cancer cells facilitates migration of the cancerous cells to localized and distal
regions via the circulatory and lymphatic systems.6 A vicious cycle of cancer cell nutrient
requirements, proliferation, angiogenesis, and mobilization persists as malignant cells invade
healthy tissue, resulting in increased severity of the cancer and metastasis to other organs.5-6,9,17
In response to the physiological changes produced by the cancerous cells, the body
activates a cell-mediated immune response within the circulatory and lymphatic systems that
involves the recruitment of white blood cells (WBCs) to combat cancerous cells through
identification and destruction.6,17 Natural Killer (NK) cells are cytotoxic lymphocytes that are
vital to and primarily responsible for the body’s natural line of defense against malignancy.67,10,17

The NK cytotoxicity against tumor cells is strengthened by the presence of interleukins, or

proinflammatory cytokines; however, interleukins have the capacity to promote stimulation of
cancer cell proliferation, angiogenesis, and metastasis of cancerous tissue, as well as
immunologic resistance.6,17 Additionally, catecholamines are often released in the body’s
response to stress and have demonstrated inhibition of cancer-fighting NK cells.17
The aforementioned physiology of cancer cell proliferation response is further
exacerbated by surgical and anesthetic conditions.3 Research suggests that surgical resection of
cancerous tissue results in metastasis due to the inadvertent shedding of malignant cells via the
systemic vasculature. Additional immunosuppressive responses secondary to surgical conditions
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that promote metastasis during the perioperative period include sympathetic nervous system
(SNS) stimulation, pain, hypovolemia, hypoxia, and hypotension; most of these responses can be
blunted or corrected with careful anesthetic intervention by the anesthesia provider.17
Several studies have identified a time-sensitive and dose-dependent immunosuppressive
effects of VAA on NK cells and lymphocytes. Suppression of NK cell activity cultivates an
environment that favors an increased risk for cancer cell proliferation, as the body is unable to
combat the circulating cancerous cells exacerbated by tumor resection intraoperatively.3,6-7,12-13,16
Various studies have evaluated the effects of VAA on immunologic suppression compared with
TIVA and identified an increase in breast cancer cell proliferation, migration, and decreased
immunologic response in patients that received VAA anesthesia.3,7-13,19 In fact, TIVA-based
anesthetic demonstrated an increase in NK cell response and suppressed malignant cell
metastasis in vitro.3-4,7-13,16-17,19 In a recent study by Yan et al, propofol-based TIVA was also
associated with decreased cyclooxygenase-2 (COX-2) activity, which is a foundational
component to the production of the aforementioned tumor-progression hormone, PGE2.11
MicroRNAs (miRNAs), single-stranded, noncoding RNA molecules, which are
responsible for transcriptional gene regulation have also been identified as tumor suppressants
via various mechanisms of cell biology.4-5,18 Researchers have identified that anesthetic agents
may directly or indirectly modulate cancer cell biology pathways, as well as, anti-cancer
immunity via alterations in miRNA expression.4,18 MiRNA is critical to the control of cell
proliferation, inflammation, and metabolism; therefore, anesthetic management may have serious
implications on the malignant cell activity in the perioperative period. For example, Ishikawa et
al compared the effects of VAA and TIVA on miRNA expression in rats, which highlighted the
pro-cancer effects of VAA on miRNA expression.18
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Given the available evidence, the choice of anesthetic may have serious implications that
impact the long-term outcomes in the breast cancer patient population. Anesthesia providers are
in the unique position to tailor an anesthetic plan of care that may influence the future of patients
presenting for breast cancer surgery; it is prudent to bridge the gap between new research and
current anesthetic practice to optimize this patient population and contribute to a paradigm shift
toward proactive cancer management in reducing breast cancer reoccurrence
and metastasis.
Scope of the Problem
According to the American Cancer Society,2 the estimated number of new invasive breast
cancer diagnoses in women in the US is approximately 281,550 for the current year, 2021.
Compared to previous years, the incidence of breast cancer has continued to climb steadily at a
rate of 0.5% despite advancements in breast malignancy detection and treatment.2 Breast cancer
is a death sentence for 1 in 39 women, or 2.6%, which mirrors the American Cancer Society’s
estimated 43,600 incidences of breast malignancy-associated deaths projected in 2021.2
Compared to the most recent Centers for Control and Disease (CDC) annual breast cancer case
report in 2018, breast cancer diagnoses have increased by 26,806 in the US in less than three
years.15 Breast cancer survival and recurrence rates are monitored over a 5-year period, as
recurrence is probable depending on the severity of the breast cancer in relation to location and
metastasis to other tissues; proliferation of malignant breast cells is associated with as low as a
28% survival rate.2
The physiological stress response activated during surgery poses many risk factors that
determine the behavior of cancerous cells and immunologic cell function; for example, surgical
resection of malignant tissue may potentiate the proliferation and circulation of tumor cells
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resulting in residual cancer and a consequential increased risk for recurrence.10 Various
anesthetic agents, such as VAA and opioids have been implicated in impairing immunologic
function and contributing to cancer metastasis via inhibition of the immunocompetent cells,
which are vital to the modulation of the stress response elicited in surgery.3-4,6-9,11-13 TIVA
anesthetic coupled with a multi-modal approach has demonstrated preservation of
immunocompetent cell function, which is responsible for the resistance to cancer cell
implantation, a well-documented precursor to cancer metastasis. 3-5, 7-13 The aforementioned
statistics and existing knowledge regarding the altered behavior of immunologic function
secondary to anesthetic method underscores the necessity for anesthesia providers to adopt
anesthetic techniques that have demonstrated a reduced risk in breast cancer cell proliferation
and associated recurrence; however, a knowledge deficit regarding the anesthetic management of
patients presenting for breast cancer surgery persists.
Consequences of the Problem
Millions of cancer-related deaths occur each year, primarily as a result of recurrence or
metastasis.1-2,4 While research regarding cancer prevention and treatment is a continual feat of
trial and error in the healthcare arena, it is crucial for all interdisciplinaries to take ownership for
their potential role in cancer prevention as it relates to modifiable risk factors. Growing evidence
demonstrates a correlation between various anesthetic techniques and recurrence in breast cancer
patients presenting for breast surgery, which highlights the critical role that the anesthesia
provider may have in optimizing the long-term outcomes of this patient population via their
anesthesia plan of care. 3-4,6-9,11-13 Breast cancer morality is primarily associated with breast
cancer recurrence and metasasis; therefore, identification of methods for recurrence preventions
is critical to reduce mortality rates in this patient population. Given that high-quality research has
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implicated the definitive association between VAA and opioid anesthetic techniques with
recurrence and metastasis in breast cancer patients, an educational module that presents the
optimal technique to mitigate recurrence and metastasis is warranted to allow anesthesia
providers to be proactive in providing evidenced based medicine in utilizing the current
empirical evidence. 3-4,6-9,11-13 Informing anesthesia providers of the benefits of implementing a
TIVA-based anesthetic plan of care to reduce the risk of recurrence and metastasis in breast
cancer patients presenting for surgical intervention can lead to a pivotal break-through in the
anesthetic management, as well as, a potential life-changing advancement in healthcare.
Knowledge Gaps
Although various studies have evaluated the effects of anesthetic management on breast
cancer recurrence and metastasis, knowledge gaps have been identified and have delayed the
standardization of the anesthetic care. In 2019, Yap and colleagues conducted a meta-analysis to
evaluate the current research regarding the correlation between anesthetic technique and cancer
outcomes, which included eight studies.20 Six of the eight studies evaluated the effects of
anesthetic agent on recurrence-free survival following breast, esophageal, and non-small cell
lung cancer, while all eight studies examined the effects of anesthetic agents on overall cancer
survival.20 In all eight studies, TIVA-based anesthesia was associated with improved recurrencefree survival and/or improved overall cancer survival, indicating TIVA is the anesthetic of choice
for cancer patients presenting for surgery.20
Although Yap and colleagues identified a positive correlation between TIVA and optimal
cancer patient outcomes, the researchers acknowledged that a propensity toward VAA anesthesia
exists in the anesthesia arena and TIVA is rarely utilized.20 Anesthesia provider preference for
VAA administration has taken precedence over existing data, as a result of conflicting
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conclusions of some studies.20 Additional knowledge gaps that have impacted the
standardization of anesthetic management in breast cancer patients includes the unknown
molecular mechanisms behind the clinical findings that associate anesthetics with direct and
indirect immunomodulation and cellular effects.5 Equally challenging, the lack of randomized
control trials in comparison to retrospective analysis studies complicates and delays the
translation of current research to standardized anesthetic management .20
Proposed Solution
Currently, there is no standardized anesthetic plan of care for the management of patients
undergoing surgical intervention for breast malignancy despite existing research that has
connected breast cancer metastasis and recurrence with VAA technique; therefore, anesthesia
providers continue to incorporate VAA and other anesthetic agents with propensity to cancer cell
proliferation into their anesthesia regimen. TIVA-based anesthetic proffers a higher probability
of favorable long-term, recurrence-free outcomes and an educational module should be presented
to anesthesia providers in an effort to shift the anesthetic plan of care for this vulnerable patient
population.
The prevalence and fatal effects of breast cancer metastasis necessitates the identification
for preventative methods; the standardization of an anesthetic approach to minimize the risk of
recurrence and metastasis in breast cancer patients is paramount. The aforementioned studies
underscore that the administration of TIVA-based anesthesia to breast cancer patients
undergoing breast surgery resists tumor cell proliferation and yields an associated reduced rate of
metastasis, compared to patients that receive a VAA-based anesthetic.3-13,16-20 TIVA anesthetic
technique in patients with breast malignancy is the most efficacious, safest anesthetic method to
optimize the long-term outcomes of breast cancer patients via the reduction in recurrence and
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metastasis and the ultimate quality of life. It is anticipated that the positive implications of
TIVA-based anesthesia on long-term patient outcomes will reflect life-saving advancements and
a standardization of anesthetic management for the breast cancer patient population with the
adoption of a TIVA approach; therefore, an educational module will inform anesthesia providers
and position them as leaders at the forefront of breast cancer surgery to utilize the best empirical
evidence and reduce the potential for breast cancer reoccurrence and metastasis through
anesthetic delivery.
Objective, Purpose, and PICO Question
The purpose of this literature review is to thoroughly analyze current research that
elucidates the probable benefits of a TIVA-based anesthetic approach, compared with VAA, to
prevent breast cancer recurrence and metastasis; thus, promoting favorable long-term outcomes
in breast cancer patients undergoing surgical intervention. Currently, there is no standardized
anesthetic plan of care for the management of patients undergoing surgical intervention for
breast malignancy despite various high-level studies that have connected breast cancer metastasis
with VAA technique; therefore, anesthesia providers continue to incorporate VAA and other
anesthetic agents with propensity to cancer cell proliferation into their anesthesia regimen,
respectively. This literature critique aims to close the existing research and knowledge-to-clinical
practice gap in the anesthesia realm with emphasis on the adoption of a TIVA-based anesthetic
approach to proffer a higher probability of favorable long-term, recurrence-free outcomes in
patients with breast malignancy presenting for breast surgery. In congruence with the primary
objectives of this literature review, the ultimate goal of this quality improvement initiative is to
cultivate a positive cultural transformation in regard to the anesthesia providers’ knowledge and
attitude in the anesthetic care of this vulnerable patient population.
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The following PICO (Population, Intervention, Comparison, and Outcome) question was
formulated based on elements depicted by Dang & Dearholt21 to evaluate this topic: (P) In
anesthesia providers (I) does an educational module on the utilization of a TIVA-based
anesthetic approach and avoidance of Volatile Anesthetic Agents (VAA) to reduce breast cancer
recurrence and metastasis (C), compared to no educational module (O) improve the knowledge
and attitude regarding the anesthetic management of patients presenting for breast cancer
surgery? The population involved in this topic includes patients with breast malignancy that
underwent radical mastectomy, while the intervention will incorporate the delivery of one of two
anesthetic methods, TIVA or VAA, utilized for the surgical procedure of those in the
investigative population. The effects of immunologic suppression and cancer cell proliferation,
as well as, recurrence and metastasis rates will be compared for each group and the respective
outcomes will be evaluated based on recurrence and metastasis occurrence. The aforementioned
question will be thoroughly examined through the literature appraisal and analysis of eight
fundamental peer-reviewed research articles.
II. Literature Search Methodology
Eligibility Criteria
The peer-reviewed articles included in this literature review were elected through careful
consideration of exclusion and inclusion criteria established to best delineate the previously
outlined objectives. Articles written within the English language published within the last ten years
with full-text availability were considered for evaluation. Articles were eliminated for
underwhelming sample size, insufficient relevance to the topic, focus on regional anesthetic
technique and other anesthetic drugs extraneous to TIVA or VAA administration, or omission of
discussion regarding the relationship of anesthetic technique to suppression of the immunologic
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response. Inclusion criteria comprised of studies that accentuated the direct effects of VAA and/or
TIVA based anesthetic methods for patients with breast cancer presenting for surgical intervention
and their subsequent influence on NK cell suppression and cancer cell dissemination and
implantation, as evidence by markers and recurrence rates. The Florida International University
(FIU) Library Database was utilized to access professional search engines to conduct research
congruent with the clinical question. The following key terms were exercised in a comprehensive
search with the proper Boolean operators and search symbols: Inhalational Agents, Volatile
Anesthetic Agents, Breast Cancer Surgery, Breast Cancer Recurrence, Breast Cancer Metastasis,
and Total Intravenous Anesthesia.
Information Sources
The Cumulative Index of Nursing and Allied Health Literature (CINAHL), Google
Scholar, and PubMed search engines were accessed via the Florida International University
(FIU) library database to compose comprehensive research. The literature review and study
selection were further directed and confined by Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.
Search Strategy
The keyword search conducted within the CINAHL and PubMed databases included the
following terms: (“Inhalational Agents” OR “Volatile Anesthetic Agents”) AND/OR (“Total
Intravenous Anesthesia”) AND (“Breast Cancer” OR “Breast Malignancy” OR “Breast Cancer
Surgery” OR “Breast Cancer Recurrence” OR “Breast Cancer Metastasis”). The keywords were
utilized independently or collectively and with the Boolean operators “OR” and “AND”
interchangeably in the literature search to yield a total of 869 articles, 517 from PubMed and 352
from CINAHL. The results produced from the aforementioned search were further refined via the
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application of a publication date filter to generate current peer-reviewed studies from the years
2011 to 2021, yielding 80 relevant articles. Duplicate articles and those written in alternative
languages were immediately eliminated from consideration, reducing the article count to 65.
Studies with inadequate sample size, lack of relevance to the topic, emphasis on regional
anesthetic technique and other anesthetic drugs unspecific to TIVA or VAA administration, or
failure to discuss the correlation of anesthetic technique to suppression of the immunologic
response were disqualified. Inclusion criteria consisted of studies that evaluated the direct effects
of VAA and/or TIVA based anesthetic methods for patients with breast cancer presenting for
surgical intervention and their effects on NK cell suppression and cancer cell dissemination and
implantation, as evidence by markers and recurrence rates. Following the modifications and
thorough assessment, twenty articles were selected and approved for analysis; however, further
evaluation of the full text resulted in the final selection of eight high-level articles for appraisal
due to their currency in relevance to present clinical practice and support of the abovementioned
outlined objectives.
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"Breast Cancer Surgery"
OR "Breast Cancer" OR
"Breast Malignancy"

AND

AND

"Volatile
Anesthetic
Agents"
(VAA) OR
"Inhalational
Agents"

"Total
Intravenous
Anesthesia"
(TIVA)

AND

AND

“Breast Cancer
Recurrence" OR “Breast
Cancer Metastasis”

Diagram 1: Keywords Search
III. Results of Literature Related to the Clinical Question Study Characteristics
Thorough evaluation of the eight elected articles revealed a consistency in themes that
guided the organization of this review and illuminated the significance of anesthetic technique in
the management of the investigative patient population. Cho, Lee, and Kim7, Lee et al10, and Yan
et al11 investigated a pivotal theme detailing the attenuating impact of VAA on immunologic
response and facilitation of cancer cell proliferation compared with the efficacy of TIVA in
suppressing the perioperative stress response. These researchers highlight the impact of anesthetic
method of the immunologic function and subsequent breast cancer recurrence and metastasis,
which intertwines with a second pertinent theme. Authors Enlund et al8 and Kim et al16 echo the
findings of the aforementioned researchers with an emphasis on reduced breast cancer recurrence
and metastasis rates in patients that received TIVA-based anesthetic compared to those that
received VAA.7-8.10-11,20
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All eight of the articles focused on the implications of the mode of anesthetic delivery in
regard to long-term cancer outcomes in patients with breast cancer presenting for surgical
intervention, with an emphasis on the adoption of a TIVA-based anesthetic approach to mitigate
the risk anesthesia-associated breast cancer recurrence or metastasis; thus, an improved quality of
life and overall survival. Two of the studies were randomized, prospective clinical trials,7,11 two
were retrospective database analyses,8,10 and the remaining study was based on a retrospective
cohort design.7 Participants in the retrospective studies were grouped into VAA versus TIVAbased anesthetic and the immunologic function and recurrence rates were analyzed in the
immediate post-operative and long-term period up to 5 years following surgical intervention.7,11
The database analyses aimed to examine and compare the recurrence, metastasis, and survival rates
of breast cancer patients that received VAA compared with those that received TIVA anesthesia
during surgical intervention.8,10 The retrospective cohort analysis sought to identify the feasibility,
safety, and efficacy of a combined local infiltration and TIVA-based anesthetic for outpatient
breast-conserving surgery (BCS) in breast cancer patients in regard to reduced recurrence and
increased survival compared to existing data implicating the detrimental effects of VAA in breast
cancer patients.16
Immunological Function Preservation Secondary to TIVA-Based Anesthetic
In a study by Cho, Lee, and Kim,7 the authors evaluated the effects of propofolremifentanil based anesthesia with postoperative ketorolac analgesia (propofol-ketorolac group)
compared with sevoflurane-remifentanil based anesthesia with postoperative fentanyl analgesia
(sevoflurane-fentanyl group) on NK cell cytotoxicity (NKCC) in patients with breast cancer
undergoing breast cancer surgery. NKCC secondary to VAA anesthetic technique and excessive
opioid administration has been designated as the culprit of increased breast cancer recurrence

20
and metastasis rates in breast cancer patients that underwent surgical intervention for breast
cancer treatment; thus, the researchers initiated this prospective randomized study to evaluate the
veracity of this trending finding from current retrospective analyses.7 Following approval by the
Institutional Review Board and Hospital Research Ethics Committee of Severance Hospital,
Yonsel University Health System, Seoul, Korea in February of 2014, the study was registered at
clinicaltrial.gov in March 2014 as NCT02089178.7 The researchers included patients aged 20-65
years old who underwent elective surgery for breast cancer with an American Society of
Anesthesiologists (ASA) physical status classification ranged I-III, whereas patients with renal or
hepatic deficiency; body mass index (BMI) exceeding 35 kg/m2; immunosuppressive disorders
or recipients of immunosuppressive therapy, including steroids within six months of surgical
intervention; existing metastatic disease; or recipients of radiation or chemotherapy were
excluded.7 Written consent was obtained from a sample of 50 patients (n = 50) and random
assignment to the propofol-ketorolac or sevoflurane-fentanyl groups was established utilizing a
computer-generated random number table, yielding 25 subjects in each group (n = 25).7 Patients
in the propofol-ketorolac group were anesthetized with propofol and remifentanil intraoperatively and treated with ketorolac for analgesia in the post-operative period, while patients in
the sevoflurane-fentanyl group were anesthetized with sevoflurane and remifentanil with
fentanyl-based analgesia post-operatively.7 The ultimate aim of the researchers of this study was
to compare the effects of each anesthesia-analgesia method on immune function (assessed by
NKCC measurement) in the preoperative and 24-hour postoperative period; secondary outcomes
evaluated included postoperative pain scores, interleukin-2 assay (IL-2), and inflammatory
responses evidenced by white blood cell (WBC), neutrophil, and lymphocyte counts.7 The
incidence of breast cancer recurrence or metastasis were assessed utilizing ultra-sound guided
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breast and abdomen examinations, in addition to full-body bone scans every six months
following surgery.7 Statistical analysis of the aforementioned variables was achieved utilizing
IBM SPSS20.0 (IBMCorp-Armonk, NY, USA) and SAS9.2 (SAS Institute Inc., Cary, NC, USA)
and continuous variables were evaluated utilizing an independent t-test or Mann-Whitney U test
following confirmation of normality of distribution with the Kolmogorov-Smirnov test;
categorical variables were assessed utilizing the X2 test or Fisher exact test.7 Variables requiring
repeated measurements including the NKCC, IL-2, total leukocyte, neutrophil, and lymphocyte
counts, as well as neutrophil-lymphocyte-ratio (NLR) were evaluated utilizing a linear mixed
model with randomized patient indicators and fixed group, time, and group-by-time effects,
which assessed the whether a change-over-time difference occurred between the two groups.7
Lastly, the researchers performed a post-hoc analysis with Bonferroni corrections to obtain
multiple comparisons and verify significant differences in the measurements between each group
and established a P-value of < 0.05 as statistically significant.7 The results of the researchers’
study indicated that while the baseline NKCC (%) was comparable between the two groups (P =
0.082), the baseline value, NKCC (%) increased in the Propofol-ketorolac group [15.2 (3.2) to
20.1 (3.5), P = 0.048], whereas it decreased in the Sevoflurane-fentanyl group [19.5 (2.8) to 16.4
(1.9), P = 0.032]; this indicates that the sevoflurane-fentanyl based anesthetic squelched the NK
cell cancer-fighting capacity in the intra- and post-operative periods and facilitated an
environment ideal for cancer cell migration and proliferation. Researchers also found that the
change of NKCC over time was significantly different between the groups (P = 0.048),
indicating that the debilitating effects of sevoflurane-fentanyl anesthetic on immunologic
cytogenic function of sevoflurane-fentanyl anesthetic can progress into the later stages of the
post-operative period.7 One patient in the sevoflurane-fentanyl cohort developed recurrence in
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the contralateral breast.7 While pain scores and post-surgical inflammatory responses remained
competitive between both cohorts, the researchers underline that ketorolac has been identified as
an analgesic that supports NK cell function.7 The researchers concluded that a TIVA-based
anesthetic with propofol and remifentanil and postoperative ketorolac analgesia supports
immunological function and; thus, reduces the risk of breast cancer recurrence and improved
chance of survival.7 The researchers identified some limitations to their study including: inability
to blind the operating room staff; the discriminative effects of each individual drug could not be
ascertained; and the post-surgical recurrence and metastasis follow-up period was restricted to
two years.7 The researchers advocate for additional studies with similar design to evaluate the
long-term effects on breast cancer recurrence and metastasis rates beyond a two year postoperative period.7 Studies that evaluate recurrence rates in 5-to-10 years following surgery would
be invaluable to the identification of the anesthetic implications for this patient population and
aid in the transition to standardized practice.
Similar to Cho, Lee, and Kim,7 a study conducted by Lee et al10 incorporated a singlecenter retrospective study design to assess the long-term effects of propofol-based TIVA
anesthetic technique on breast cancer recurrence and overall survival in patients that underwent
modified radical mastectomy for breast malignancy secondary to immunological compromise.
The researchers exercised a quantitative data collection which included rates of recurrence-free
survival and overall survival in the VAA and TIVA group, respectively, and facilitated statistical
analysis.10 Lee et al10 utilized an electronic database to access all patients that underwent
modified radical mastectomy from January 2007 to December 2008 to yield an adequate sample
size of 363 modified radical mastectomy cases, 173 of which were TIVA-based with propofol
and 152 that were VAA-based with sevoflurane. The exclusion criteria were clearly defined, as
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well as, demographic data and the methodology of instituting a power 0.3 software to validate
that the sample size was sufficient to accurately reflect the impact of anesthetic technique on
recurrence.10 The primary outcomes of the study included recurrence-free survival and overall
survival during the initial 5 years following modified radical mastectomy (MRM) for breast
cancer.10 The researchers delineated recurrence-free as from the date of surgery to the date of
first recurrence, which was further deciphered as locoregional recurrence or distant metastases
confirmed via clinical evidence or radiological examination, whereas overall survival was
defined as the date of surgery to the date of death.10 The researchers’ statistical analytical
methods mirrored those of Cho, Lee, and Kim;7 however, recurrence-free survival and overall
survival rates were estimated utilizing the Kaplan Meier log-rank test and Cox proportional
hazards regression was exercised to uni- and multivariate analysis of perioperative and clinically
pathologic variables that influence recurrence-free survival.10 Variables with a P-value less than
0.25 (P < 0.25) from the univariate analysis were considered meaningful and incorporated in the
multivariate analysis to identify statistically significant outcomes with a P < 0.05.10 The results
demonstrated statistical significance, as the propofol TIVA-based anesthetic group was
associated with lower rate of recurrence-free survival with a P-value of 0.037 and an estimated
hazard ratio of 0.550, a 95% CI 0.311-0.973.10 Alternate results of this study evaluated the pain
management of each of the respective cohorts. Unlike the comparability of pain management
identified by Cho, Lee, and Kim7 between the sevoflurane and propofol-based cohorts, Lee et
al10 found that the TIVA-based propofol group required more opioid administration in the perioperative period. In alignment with the conclusion of Cho, Lee, and Kim,7 Lee et al10 the authors
concluded that propofol-based TIVA significantly reduced breast cancer recurrence after
modified radical mastectomy due to the immunologic-protective effects. The authors
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acknowledged study limitations, which included the retrospective design, lack of randomization,
and single-site evaluation in an effort to eliminate inconsistencies in surgical and medical
methods that may have altered the results.10 Although the authors recommend additional multicenter prospective studies to validate their findings, the endorsement of TIVA-based anesthetic
approach in breast cancer patients presenting for breast surgery is strongly supported to reduce
the inherent risk of immunologic suppression and associated potentiation of recurrence and
metastasis.
Yan et al11 evaluated the implications of a TIVA-based anesthetic for breast cancer
resection due to its correlation with decreased tumor growth and metastasis compared to an VAA
approach utilizing a comprehensive, randomized controlled clinical study design. The
researchers randomly assigned 80 (n =80) patients undergoing breast cancer resection to either a
propofol/remifentanil-based or sevoflurane-based anesthetic technique via an envelope reveal on
arrival to the operating room (OR). Vascular endothelial growth factor (VEGF) and transforming
growth factor (TGF), markers associated with tumor growth and proliferation, were analyzed 24
hours following surgery and recurrence-free survival (RFS) rates were assessed over a two-year
follow-up period.11 The statistical findings were significant as evidence by preoperative and
postoperative great difference in VEGF between the VAA (50) and TIVA (12) groups, reflective
of a P-value of 0.008.11 Additionally, the two-year recurrence-free survival rates were 78% and
95% in the VAA and TIVA groups, respectively.11 These results led the researchers to conclude
that TIVA-based anesthetic technique can “effectively inhibit the increases” in cancer marker
concentrations after surgery compared with VAA; thus, potentiating the possibility of recurrence
and metastasis secondary to anesthetic mode of delivery.11 Limitations included a limited sample
size, failure to conduct the study with a multi-center design, and the desire for a longer term
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follow-up period to clarify the roles of each anesthetic modes on recurrence and metastasis of
breast cancer.11 An additional limitation addressed the fact that a small bolus of propofol and
fentanyl were administered to each cohort upon induction of anesthesia; however, the effects of
single-dose propofol administered to the sevoflurane-based group would have dissipated within
ten minutes and anesthesia was maintained with sevoflurane throughout the intra-operative
period. The results obtained from Yan et al11 echo the findings of the previously mentioned
studies and highlight the significance of anesthetic approach in the quality of life for breast
cancer patients undergoing surgical intervention.
In an effort to demonstrate the direct effects of anesthetic agents on recurrence and
metastasis, Connolly et al4 completed a retrospective analysis to evaluate the association between
genetic expression of anesthetic-analgesic receptor targets and recurrence and metastasis,
utilizing a repository of malignant breast tissue gene expression and correlating clinical data. The
researchers included 23 genes with the most prominent anesthetic-analgesic receptor targets
frequented in the current anesthetic management of patients with breast malignancy presenting
for surgery. Connolly et al4 utilized an algorithm via Breastmark, to integrate the gene expression
data from approximately 17,000 samples and clinical data from greater than 4,500 breast cancer
samples. The gene expression data was dichotomized according to disease-free survival, or
survival without recurrence, and distant disease-free survival, or survival without metastasis;
whereas, hazard ratios were achieved via a Cox-regression analysis for each group, respectively.
Prognostic markers were determined via the randomized selection from the 23-member gene lists
from all available genes, in addition to, a calculation for each occurrence in which more than 5
significant markers were observed.4 After 10,000 repetitions of the aforementioned process, the
researchers calculated an empirical P-value to determine statistical significance. The researchers
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identified that 9 of the 23 genes were significantly associated with altered rates of metastasis and
4 of 23 with recurrence. Although a P-value of 0.07 failed to demonstrate statistical significance
for metastasis after adjustments for multiple testing, the researchers emphasize that several
anesthetic and analgesic agents, such as VAA and opioids, utilized in the management of breast
cancer patients demonstrated a propensity for the metastatic spread of breast cancer compared to
others anesthetic agents, including propofol.4 Connolly et al4 highlight that the effects of
anesthetic agents may potentiate or mitigate the proliferation and metastasis of breast cancer on a
molecular level; therefore, having drastic implications on the long-term outcomes in patients
with breast malignancy presenting for surgical intervention.
Breast Cancer Recurrence and Metastasis Secondary to Anesthetic Technique
Enlund et al8 conducted a retrospective, multicenter database analysis from seven
Swedish hospitals to evaluate and compare the effects of TIVA propofol-based and VAA
sevoflurane-based anesthetic delivery in breast cancer surgery patients in regard to long-term
recurrence and breast cancer survival. The researchers distinguished all breast cancer patients
that underwent breast cancer surgery from 2006 to 2012, which were matched to the Swedish
Breast Cancer Quality Register to ascertain specific tumor characteristics, prognostic factors,
adjuvant therapies, and date of expiry.8 A total of 6305 patients (n = 6305) were included in the
database analysis; 3096 subjects (n = 3096) received propofol-based anesthesia intraoperatively,
while 3209 subjects (n = 3209) received a sevoflurane-based anesthetic.8 The survival rates for
the sample were assessed at 1- and 5-years following surgical intervention utilizing the multiple
Cox regression models adjusted accordingly for demographic, oncological, and multi-control
variables, as well as, propensity score (PS) matching for the same variables including a separate
analysis to accommodate the participating hospitals as a cofactor.8 The researchers exercised two
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Cox regression models for each of the anesthetic delivery groups; propofol or sevoflurane-based
cohorts, respectively. Each regression model were concisely adjusted for age, classification,
histopathology, adjuvant therapies, and specific intervention (total or partial mastectomy, sector
resection, with or without axillary clearance, and supplemental breast surgery).8 PS were
calculated with an emphasis of the treatment for each cohort as the dependent variable and
adjusted for the aforementioned criteria, yielding a five PS matching cohorts for estimation.8
Following the application of a Cox regression model, the authors identified a P-value less than
0.05 (P < 0.05) as statistically significant.8 Enlund et al8 identified that the survival rates for the
cohorts were 81.8% and 91.0% for the sevoflurane and propofol cohorts, respectively; yielding a
P-value of 0.126 (P = 0.126). The researchers delineated that different results obtained fluctuated
depending on the application of the varying statistical adjustment methods utilized; however, a
proposed and determined difference in survival favored the propofol-based anesthetic across the
board with up to a 9.2 percentage increase in survival rate at 5-years following surgical
intervention.8 The increased 5-year survival rate of the propofol-based cohort is reflected by a
hazard ratio of 1.46, 95% CI 1.10-1.95.8 Congruent with the findings of the researchers in the
above mentioned studies, Enlund et al8 determined that general anesthesia with a TIVA propofolbased anesthetic approach is beneficial regarding long-term outcome following primary breast
cancer surgery compared with VAA sevoflurane-based anesthesia, in terms of overall survival.8
The authors acknowledge that the retrospective nature of their study as a limitation and urge the
completion of randomized control trials to further establish the validity of their findings.8
A retrospective analysis conducted by Enlund et al13 focused on the correlation between
anesthetic technique and patient survival following radical cancer surgery.13 Similar to the
previous researchers, Enlund et al13 compared the differences in the overall 1- and 5-year
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survival rates of patients that underwent surgical intervention for breast, colon, or rectal
malignancy and received either a propofol-based TIVA anesthetic or sevoflurane-based VAA
anesthetic. The researchers accessed a database to select 2,838 patients (n= 2,838) that
underwent breast (n= 1,837), colon (n= 695), or rectal (n= 306) cancers and were record-linked
to regional clinical quality registers.13 Cumulative 1- and 5-year overall survival rates were
achieved utilizing the Kaplan-Meier method, and estimates were compared between patients that
received a propofol-based anesthetic (n = 903) or sevoflurane-based anesthetic (n = 1,935).13
The researchers incorporated Cox proportional hazard models to calculate and assess the risk of
death adjusted for potential effect modifiers and confounders for accuracy.13 The results from the
statistical analysis reflected an obvious advantage of a propofol-based anesthetic in the
management of cancer patients presenting for surgery with in the overall 1- and 5-year survival
rate of 4.7% (P = 0.004) and 5.6% (P < 0.001), respectively for all cancer types combined.13
Enlund et al13 advocate that TIVA anesthetic technique with propofol improves the overall
quality of life and chance of survival in cancer patients presenting for surgery.
Safety, Efficacy, and Feasibility of TIVA-based Anesthetic
Kim et al16 in 2020, conducted a retrospective cohort analysis to examine the safety,
efficacy, and feasibility of a combined local and TIVA anesthetic and/or sedation in relation to
the overall effects of this less-immunosuppressive anesthetic approach on reduced breast cancer
recurrence and survival.16 The researchers underscore that the administration of inhalational
anesthetic agents in breast cancer patients undergoing surgical intervention is an associated
trigger for increased mortality secondary to breast cancer recurrence linked to VAA anestheticassociated immunosuppression during the perioperative period. Kim et al16 explored this
alternate anesthetic approach to circumvent the jeopardy of an ineffective cytotoxic response.

29
The researchers’ study was comprised of 456 patients (n = 456) diagnosed with stage 0-III breast
cancer who underwent outpatient breast conserving surgery (BCS) or axillary lymph node (ALN)
management with a combined local-TIVA based anesthetic from March 2008 to January 2020.16
Of the 456 patients included, the ages ranged from 27 to 91 years and the clinical stages
dispersed among the subjects were as follows: 267 (58.4%) patients were diagnosed with stage 0
or I malignancy, 165 (36.1%) patients with stage II malignancy, and 24 (5.2%) patients with
stage III malignancy.16 The researchers established a median follow-up period of 2259 days
during the 11.4 year-period of their study to evaluate the overall survival and breast cancerspecific survival rates of the patients included in the study.16 Survival rates included the
pathological tumor size, ALN metastasis, or no metastasis (pN0); 1.9% with complete tumor
reduction following NAC, 36.1% of patients, and 76.5% of patients, respectively.16 Tumor
subtypes accounted for this study yielded a total of 325 of patients with hormone receptor–
positive and human epidermal growth factor receptor 2 (HER2)-negative tumors, 58 patients
with HER2-positive tumors, and 17 (3.7%) patients with triple negative (TN) breast cancer.16
Unlike the samples in the previously mentioned studies, Kim et al16 included patients that
received adjuvant chemotherapy and/or endocrine and radiotherapy following surgical
intervention based on tumor subtype and the primary pathological tumor findings.16 Patients that
requiring radiation for salvaged breast tissue received standard dosing with or without additional
boosters as needed; 3-4 weeks for hypofractionated doses or 4-5 weeks post-operatively. Those
that required neoadjuvant treatment with chemo or endocrine therapy were treated 6 months
prior to surgical intervention, while all patients with stage II and stage III malignancy received
neoadjuvant therapy.16 Statistical analysis was achieved utilizing a Statcel 4 (OMS Publishing
Inc., Saitama, Japan) to ascertain cumulative overall survival (OS) and breast-cancer specific
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survival (BCSS) rates; Kaplan-Meier method was employed to determine survival rates
according to pathological stage (pStage) and tumor subtype.16 Kim et al16 compared the data
between each group utilizing the log-rank test and elected P-values less than 0.05 (P < 0.05) as
statistically significant. The researchers’ statistical analysis revealed OS and BCSS rates of
92.3% and 94.7%, respectively. The OS rates for pStages 0–III disease were 93.5%, 94.1%,
90.0%, and 71.4%, respectively (P = 0.017), while the OS rates for L, L- HER2, HER2, and TN
breast cancers were 93.4%, 93.1%, 83.3%, and 64.2%, respectively (P = 0.002).16 The BCSS
rates for pStages 0–III disease were 97.9%, 95.9%, 92.7%, and 71.4%, respectively (P = 0.001),
while the BCSS rates for L, L-HER2, HER2, and TN breast cancers were 94.8%, 93.1%, 83.3%,
and 83.3%, respectively (P = 0.130).16 Overall, the researchers observed a recurrence rate as low
as 5.4%, or 25 patients. The results supported the original hypothesis that outpatient surgery for
breast cancer patients requiring BCS and ALN management under a combined local-TIVA
anesthetic delivery model is an immunologic protective anesthetic method to reduce breast
cancer recurrence and improve overall survival, in contrast to VAA-based anesthesia.16
Ní Eochagáin et al3 conducted a retrospective analysis of an on-going randomized control
trial (RCT) NCT00418457 to evaluate and compare the effects of a propofol-paravertebral and
inhalational agent-opioid anesthetic technique on the neutrophil-lymphocyte ratio (NLR) during
the post-operative period in patients that underwent breast cancer surgery. The researchers
accentuate that the administration of a propofol-paravertebral technique may be the safest, most
efficacious anesthetic technique to optimize the post-operative immune response in breast cancer
patients presenting for surgical intervention, thus reducing the risk of long-term breast cancer
recurrence and metastasis.3 Ní Eochagáin et al3 included 116 participants (n =116), which were
randomly assigned to either the propofol-paravertebral anesthesia (n = 59) or inhalational agent-

31
opioid anesthesia (n = 57) groups.3 The propofol-paravertebral group received a thoracic epidural
catheter with an initial test dose consisting of 1.5% lidocaine and 1:200,000 epinephrine and a
10-20mL bolus of 0.5% bupivacaine or 0.5% ropivacaine, followed by a supplementary
intravenous propofol infusion titrated to effect with a range of 60-90 mcg/kg/min.3 A continuous
epidural infusion of 0.5% bupivacaine or 0.5% ropivacaine at a rate of 6-10 mL/hour was
initiated toward the end of surgery and continued up to 48 hours post-operatively, where
additional analgesia via the administration of non-steroidal anti-inflammatory (NSAID) or
paracetamol medications served as adjuvants for breakthrough pain.3 The inhalational agentopioid anesthesia group received general anesthesia that consisted of induction via the
administration of 1-3 mcg/kg of fentanyl and 2-4 mg/kg of propofol and maintenance with
sevoflurane, titrated to maintain the heart rate and blood pressure within 20% of baseline values
and an adequate anesthetic plane.3 Toward the end of surgery, 0.1 mg/kg of intravenous
morphine was administered toward the end of surgery and long-acting intravenous opioid
analgesics were administered as needed in the post-operative period via nurse-controlled or
patient-controlled analgesia.3 Both groups were transitioned to paracetamol and NSAIDs
approximately 24 hours post-operatively. Complete blood count (CBC) was drawn for the
patients in each group in both the pre- and post-operative periods and the NLR were compared to
identify a baseline, as well as, deviation from the baseline NLR following intervention.3 While
the pre-operative NLR for the patients in each group were comparable, the post-operative NLR
was significantly lower in the propofol-paravertebral anesthesia group (3.0 (2.4-4.2) compared to
the inhalational-opioid anesthesia group (4.0 (2.9-5.4), reflecting a P-value of P = 0.001.3 Ní
Eochagáin et al3 underscore that existing data suggests an NLR greater than 3.0 in the postoperative period is associated with an increased risk of breast cancer recurrence and metastasis;
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therefore, the selection of a propofol-paravertebral anesthetic for breast cancer patients
undergoing surgical intervention is likely to yield more favorable long-term, recurrence-free
outcomes compared to an inhalational agent-opioid anesthetic.3
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Purpose

Ní
Eochagáin
et al3

Inflammation and
immunosuppression
contribute to the
pathogenesis of
cancer. An increased
neutrophil–
lymphocyte ratio
reflects these
processes and is
associated with
adverse cancer
outcomes. Whether
anesthetic technique
for breast cancer
surgery influences
these factors, and
potentially cancer
recurrence, remains
unknown.
Researchers
conducted a
secondary analysis in
patients enrolled in an
ongoing trial of
anesthetic technique
on breast cancer
recurrence. The
primary hypothesis
was that postoperative
neutrophil–
lymphocyte ratio is
lower in patients
allocated to receive
propofolparavertebral rather
than inhalational
agent-opioid
anesthesia for primary
breast cancer
surgery.3

Methodology/
Research
Design
Retrospective
Analysis of ongoing
Randomized
Control Trial:
NCT00418457

Intervention(s)/
Measures

Sampling/ Setting

Primary
Results

Relevant Conclusions

Patients were
randomly allocated to
receive either a
propofolparavertebral
anesthetic with
propofol-based TIVA
and paravertebral
block or an
inhalational agentopioid anesthetic with
sevoflurane and
morphine. The Preand Post-operative
neutrophil–
lymphocyte ratio
(NLR) was compared
for each group.13

A total of 397
participants were
enrolled in NCT
00418457 up to 31
October 2016 at the
Mater University
Hospital. Among
these, 10
participants
withdrew from the
study, four had
incomplete records
and 267 lacked
both a preoperative and a
postoperative full
blood count within
three days of their
primary surgery.
Therefore, the
charts of 116
participants were
included in this
retrospective
analysis, with 59
randomly allocated
to propofolparavertebral
anesthesia and 57
to inhalational
agent-opioid
anesthesia.3

Among 397
patients, 116
had differential
white cell
counts
performed preoperatively and
postoperatively.
Pre-operative
neutrophil–
lymphocyte
ratio was
similar in the
propofolparavertebral
2.3 (95% CI
1.8–2.8) and
inhalational
agent-opioid
anesthesia 2.2
(1.9–3.2)
groups,
P = 0.72.
Postoperative
neutrophil–
lymphocyte
ratio was lower
(3.0 (2.4–4.2)
vs. 4.0 (2.9–
5.4), p = 0.001)
in the propofolparavertebral
group.3

The propofolparavertebral group
demonstrated statistically
significant results for
attenuating post-operative
increase in the NLR.3
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Connolly
et al4

Evaluate the
association between
the genetic expression
of anestheticanalgesic receptor
targets and recurrence
and metastasis in
breast cancer tissue.4

Retrospective
Analysis

A list of 23 genes
encoding for the most
prominent anestheticanalgesic receptor
targets were
compiled. and
processed via
Breastmark, an
algorithm integrating
gene expression data
from ~17,000
samples and clinical
data from >4,500
breast cancer
samples. Gene
expression data was
dichotomized
utilizing disease-free
survival, or survival
without recurrence,
and distant diseasefree survival, or
survival without
metastasis as end
points. Hazard ratios
were calculated by
Cox-regression
analysis. Enrichment
for prognostic
markers was
determined by
randomly choosing
23-member gene lists
from all available
genes, calculating
how often >5
significant markers
were observed and
adjusting p-values for
multiple testing. This
was repeated 10,000
times and an
empirical p-value
calculated.4

A total of 23 genes
were evaluated in
the gene expression
data from 17,000
samples and
clinical data from
more than 4,500
breast tumor
samples.4

Of 23 selected
genes, 9 were
significantly
associated with
altered rates of
metastasis and
4 with
recurrence on
univariate
analysis.
Adjusting for
multiple
testing, 5 of
these 9 genes
remained
significantly
associated with
metastasis.4
This ratio of
genes (5/23)
was not
significantly
enriched for
markers of
metastasis (p =
0.07); however,
a trend of
metastasis was
observed
specific to
several
anestheticanalgesic
agents.4

Several anestheticanalgesic receptor genes
were associated with
metastatic spread in
breast cancer. Overall
there was no significant
enrichment in prognostic
markers of metastasis,
although a trend was
observed.4
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Cho, Lee,
and Kim7

Compare the effects
of two different
anesthesia and
analgesia methods
[propofolremifentanil
anesthesia with
postoperative
ketorolac analgesia
(Propofol-ketorolac
groups) VS
sevofluraneremifentanil
anesthesia with
postoperative fentanyl
analgesia
(Sevoflurane-fentanyl
group)] on the NK
cell cytotoxicity
(NKCC) in patients
undergoing breast
cancer surgery.7

Prospective
Randomized
Study

Fifty patients
undergoing breast
cancer resection were
randomly assigned to
either the PropofolKetorolac or
Sevoflurane-Fentanyl
anesthesia groups.
The primary outcome
was NKCC, which
was measured before
and 24 h after
surgery. Post-surgical
pain scores and
inflammatory
responses measured
by white blood cell,
neutrophil, and
lymphocyte counts
were assessed. Cancer
recurrence or
metastasis was
evaluated with
ultrasound and
whole-body bone
scan every 6 months
for 2 years after
surgery.7

A total of 50
patients (20-65
years old) who
underwent elective
surgery for breast
cancer and had an
American Society
of
Anesthesiologists
(ASA) physical
status classification
of I to III were
randomly assigned
into one of the
study groups (25
patients each) using
a computergenerated random
number table and
assignments were
concealed in an
envelope. The
Propofol-ketorolac
group, patients
were anesthetized
with propofol and
remifentanil and
received ketorolac
after surgery,
whereas the
Sevofluranefentanyl group,
patients were
anesthetized with
sevoflurane and
remifentanil and
received fentanyl
postoperatively.7

The baseline
NKCC (%) was
comparable
between the
two groups (P
= 0.082).
Compared with
the baseline
value, NKCC
(%) increased
in the Propofolketorolac group
and decreased
in the
Sevofluranefentanyl group
[15.2 (3.2) to
20.1 (3.5), P =
0.048] and
[19.5 (2.8) to
16.4 (1.9), P =
0.032],
respectively.
The change of
NKCC over
time was
significantly
different
between the
groups (P =
0.048). Pain
scores during
48 h after
surgery and
post-surgical
inflammatory
responses were
comparable
between the
groups. One
patient in the
Sevofluranefentanyl group
had recurrence
in the
contralateral
breast and no
metastasis was
found in either
group.7

Propofol anesthesia with
postoperative ketorolac
analgesia demonstrated a
favorable impact on
immune function by
preserving NKCC
compared with
sevoflurane anesthesia
and postoperative
fentanyl analgesia in
patients undergoing
breast cancer surgery.7
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Enlund et
al8

Retrospective studies
indicate that the mode
of anesthetic impacts
long-term cancer
survival secondary to
the reduction in breast
cancer recurrence.
Researchers gathered
a large cohort of
breast cancer surgery
patients from seven
Swedish hospitals and
hypothesized that
general anesthesia
with propofol would
be superior to
sevoflurane
anesthesia regarding
long-term breast
cancer survival.8

Retrospective,
Multicenter
Database
Analysis

Researchers identified
all patients that were
anaesthetized for
breast cancer surgery
between 2006 and
2012. The patients
were matched to the
Swedish Breast
Cancer Quality
Register, to retrieve
tumor characteristics,
prognostic factors,
and adjuvant
treatment, as well as,
date of death. Overall
survival between
patients that
underwent
sevoflurane and
propofol anesthesia
was analyzed with
different statistical
approaches: (a)
multiple Cox
regression models
adjusted for
demographic,
oncological, and
multiple control
variables, (b)
propensity score
matching on the same
variables, but also
including the
participating centers
as a cofactor in a
separate analysis.8

All patients
anesthetized for
primary breast
cancer surgery
between 1998 and
2012 were retrieved
from each
participating
hospital’s database
(Borås, Kalmar,
Lund, Sundsvall,
Uppsala, Västerås,
and Örebro
hospital). The
database analysis
identified 6305
patients.8

The 5-year
survival rates
were 91.0%
and 81.8% for
the propofol
and sevoflurane
group,
respectively, in
the final model
(P = .126).
Depending on
the statistical
adjustment
method used,
different results
were obtained,
from a nonsignificant to a
"proposed" and
even a
"determined"
difference in
survival that
favored
propofol, with a
maximum of
9.2 percentage
points higher
survival rate at
5 years (hazard
ratio 1.46, 95%
CI 1.10-1.95).8

General anesthesia with
propofol is beneficial
regarding long-term
outcome following
primary breast cancer
surgery compared with
general anesthesia with
sevoflurane, in terms of
overall survival.8
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Lee et al10

Examine the link
between propofolbased total
intravenous
anesthesia (TIVA)
and recurrence or
overall survival in
patients undergoing
modified radical
mastectomy (MRM),
compared to patients
that received
sevoflurane-based
anesthetic.10

Single-Center,
Retrospective
Cohort
Analysis

A retrospective
analysis of the
electronic database of
all patients
undergoing MRM for
breast cancer between
January 2007 and
December 2008 was
undertaken. Patients
received either
propofol-based TIVA
(propofol group) or
sevoflurane-based
anesthesia
(sevoflurane group).
We analyzed
prognostic factors of
breast cancer and
perioperative factors
and compared
recurrence-free
survival and overall
survival between
propofol and
sevoflurane groups.10

Researchers
reviewed the
electronic medical
records of 363
patients who
underwent MRM
for invasive ductal
carcinoma of the
breast between
January 2007 and
December 2008;
325 cases were
suitable for analysis
(173 cases of
propofol group, and
152 cases of
sevoflurane group).
There were
insignificant
differences
between the groups
in age, weight,
height,
histopathologic
results, surgical
time, or
postoperative
treatment
(chemotherapy,
hormonal therapy,
and radiotherapy).10

The use of
opioids during
the
perioperative
period was
greater in
propofol group
than in
sevoflurane
group. Overall
survival was no
difference
between the
two groups.
Propofol group
showed a lower
rate of cancer
recurrence (P =
0.037), with an
estimated
hazard ratio of
0.550 (95% CI
0.311–0.973).10

This retrospective study
provides the possibility
that propofol-based TIVA
for breast cancer surgery
can reduce the risk of
recurrence during the
initial 5 years after
MRM.10
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Yan et
al11

Vascular endothelial
growth factor (VEGF)
and transforming
growth factor-β
(TGF-β) have been
involved in tumor
growth and
metastasis.
Sevoflurane may
promote
angiogenesis, whereas
propofol can present
an anti-angiogenic
effect. In this study,
researchers compared
the effects of
propofol/remifentanilbased total
intravenous
anesthesia (TIVA)
and sevofluranebased inhalational
anesthesia on the
release of VEGF-C
and TGF-β, as well
as, recurrence- free
survival (RFS) rates
in the patients
undergoing breast
cancer surgery.11

Prospective,
Randomized,
Controlled
Parallel-Group
Clinical Trial

Eighty female
patients undergoing
breast cancer
resection were
enrolled and
randomized to receive
either sevofluranebased inhalational
anesthesia (SEV
group) or
propofol/remifentanilbased TIVA (TIVA
group). The serum
concentrations of
VEGF-C and TGF-β
before and 24 h after
surgery were
measured and RFS
rates over a two-year
follow-up were
analyzed in both
groups. The
postoperative pain
scores assessed using
a visual analogue
scale (VAS) and the
use of perioperative
opioids were also
evaluated.11

After taking written
informed consent,
adult female
patients aged 18 to
80 years, ASA
physical status I
and II, undergoing
MRM or BCS for
confirmed breast
cancer were
enrolled in the
study. The patients
were randomly
assigned to receive
propofol/
remifentanil -based
TIVA (TIVA
group) or
sevoflurane- based
inhalational
anesthesia (SEV
group).
Randomization was
done using a sealed
envelope system. A
physician (Dr. Liu)
not involved in the
study randomly
inserted 50 of each
two anesthetic
designations to 100
sequentially
numbered
envelopes. The
allocation sequence
was generated
using a random
number generator.
The envelop was
opened before
anesthetic
induction by the
investigators to
determine which
anesthetic
technique was
going to be
performed.11

Although VAS
scores at 2 h
and 24 h after
surgery were
comparable
between the
two groups,
there were
more patients
receiving
postoperative
fentanyl in the
TIVA group
(16[40%])
compared with
the SEV group
(6[15%], p =
0.023). VEGFC serum
concentrations
increased after
surgery from
105 (87–193)
pg/ml to174
(111–281)
pg/ml in the
SEV group (P
= 0.009), but
remained
almost
unchanged in
the TIVA
group with 134
(80–205) pg/ml
vs.140(92–250)
pg/ml(P =
0.402). The
preoperative to
postoperative
change for
VEGF-C of the
SEV group (50
pg/ml) was
significantly
higher than that
of the TIVA
group (12
pg/ml) with a
difference of 46
(− 11–113)
pg/ml (P =
0.008). There
were also no
significant
differences in
the
preoperative
and
postoperative

In comparison with
sevoflurane-based
inhalational anesthesia,
propofol/remifentanil based total intravenous
anesthesia can effectively
inhibit the release of
VEGF-C induced by
breast surgery.11
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TGF-β
concentrations
between the
two groups.
The two-year
RFS rates were
78% and 95%
in the SEV and
TIVA groups
(P = 0.221),
respectively.11
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Enlund et
al13

Several clinical
studies have
illuminated that
commonly used
inhalational agents,
such as sevoflurane,
are pro-inflammatory,
whereas the
intravenously
administered hypnotic
agent propofol is antiinflammatory and
anti-oxidative. This
retrospective analysis
examined the possible
association between
patient survival after
radical cancer surgery
and the use of
sevoflurane or
propofol anesthesia.13

Retrospective
Analysis

Demographic,
anesthetic, and
surgical data from
2,838 patients
registered for surgery
for breast, colon, or
rectal cancers were
included in a
database. This was
record-linked to
regional clinical
quality registers.
Cumulative 1- and 5year overall survival
rates were assessed
utilizing the KaplanMeier method, and
estimates were
compared between
patients given
propofol (n = 903) or
sevoflurane (n =
1,935). In a second
step, Cox
proportional hazard
models were
calculated to assess
the risk of death
adjusted for potential
effect modifiers and
confounders.13

A database was
accessed to retrieve
surgical data from
2,838 patients that
underwent surgical
intervention for
breast, colon, or
rectal cancers. The
sample size was
further analyzed to
compare the 1- and
5-year overall
survival rates
between the
propofol-based
TIVA group (n=
903) or
sevoflurane-based
VAA group (n=
1,935).13

Differences in
overall 1- and
5-year survival
rates for all
three sites
combined were
4.7% (p =
0.004) and
5.6% (p <
0.001),
respectively, in
favor of
propofol.13

Propofol-based TIVA
suggests favorable longterm outcomes in patients
undergoing radical cancer
surgery, compared with
VAA-based anesthetic.
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Kim et
al16

The use of general
anesthesia (GA) with
inhalational
anesthetics for breast
cancer surgery may
be associated with
breast cancer
recurrence and
increased mortality
due to the
immunosuppressive
effects of these drugs.
Lessimmunosuppressive
anesthetic techniques
may reduce breast
cancer recurrence.
We evaluated the
feasibility, safety, and
efficacy of outpatient
breast-conserving
surgery (BCS) for
breast cancer in a
breast clinic in terms
of the anesthetic
technique used,
complications
occurring, recurrence,
and survival utilizing
local and intravenous
anesthesia and/or
sedation.16

Retrospective
Cohort
Analysis

The sample
comprised 456
consecutive patients
with stage 0–III
breast cancer who
underwent
BCS/axillary lymph
node (ALN)
management using
local and intravenous
anesthesia and/or
sedation between
May 2008 and
January 2020. Most
patients received
adjuvant
chemotherapy and/or
endocrine therapy and
radiotherapy after
surgery. Patient
outcomes were
evaluated
retrospectively.16

Breast cancer
recurrence and
associated
mortality were
examined in a
sample of 456
consecutive
patients with breast
cancer undergoing
BCS and ALN
management under
local and IV
anesthesia and/or
sedation in the
outpatient setting of
a breast clinic. The
researchers
hypothesized that
the use of lessimmunosuppressive
anesthetic
approaches with
local and IV anesthesia and/or
sedation with the
maintenance of
spontaneous
breathing would
improve the
survival of patients
with breast
cancer.16

All patients
recovered and
were
discharged after
resting for 3–4h
postoperatively.
No procedurerelated severe
complication or
death occurred.
The median
follow-up
period was
2259 days
(range, 9–4190
days), during
which disease
recurrence was
observed in 25
(5.4%) patients.
The overall
survival and
breast cancer–
specific
survival rates
were 92.3%
and 94.7%,
respectively.16

Outpatient surgery for
breast cancer involving
BCS and ALN
management under local
and intravenous
anesthesia and/or
sedation can be
performed safely, without
serious complication or
death. Lessimmunosuppressive
anesthetic techniques
with spontaneous
breathing may reduce the
recurrence of breast
cancer and improve
survival relative to GA.16

IV. Summary of the Supporting Evidence
Current research strongly suggests a direct correlation between VAA-based anesthetic
and immunologic suppression and ultimate contribution to morality secondary to anesthesiaassociated breast cancer recurrence.3-13,16-22 Despite existing evidence, a standardization for the
anesthetic management of breast cancer patients undergoing surgical interventions has yet to be
implemented; thus, researchers continue to pursue studies to heighten awareness amongst
anesthesia providers to encourage the professional, evidence-based decision to employ a TIVAbased anesthetic for this patient population to maximize their opportunity at cancer-free survival
following surgery.7-8,10-11,16 All authors of the abovementioned studies concluded that TIVA-
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based anesthesia lacks the immunosuppressive effects identified with VAA administration in
breast cancer patients.7-8,10-11,16
While all eight of the studies shared consistent themes, Ní Eochagáin et al,3 Connolly et
al,4 Cho, Lee, and Kim,7 Lee et al,10 and Yan et al,11 placed emphasis on the effects of anesthesia
with inhalational anesthetics on immunologic function compared to TIVA in patients with breast
malignancy undergoing surgical intervention. All authors identified that VAA-based anesthesia
resulted in immunologic suppression via various mechanisms that led to an impaired cytotoxic
environment; thus, facilitating cancer cell migration and proliferation and ultimate recurrence
and metastasis.7,10-11 Enlund et al,8 Enlund et al,13 and Kim et al16 constructed their studies with a
foundational purpose on recurrence, metastasis, and survival rates in breast cancer patients that
underwent breast cancer surgery with either a VAA or TIVA-guided anesthetic; this was a
secondary theme addressed in the previously mentioned studies.7,10-11 The authors from each
study identified a statistically significant reduction in breast cancer recurrence, metastasis, and/or
survival rates in patients that received a TIVA-based anesthetic during their surgical
intervention.7-8,10-11,16
The results from the eight studies included in this review underscore the significance of
increasing anesthesia provider knowledge in regard to the implications of anesthetic delivery on
the long-term outcomes of the target patient population. Eliminating the knowledge deficit and
bridging the gap between current evidence-based research and clinical practice in the anesthesia
arena with an educational module will provide anesthesia providers with the tools necessary to
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provide the safest, efficacious TIVA-based anesthetic to breast cancer patients presenting for
surgery, ultimately fostering a greater chance at breast cancer survival.
V. Primary DNP Project Goal
Metastasis is documented as the primary cause of mortality in the breast cancer patient
population with rates as high as 25%.3-6 As a result of increased breast malignancy diagnoses, the
number of women undergoing surgical resection of breast malignancies to manage their
diagnosis are frequent in operating rooms at a higher rate; thus, forcing anesthesia providers into
the difficult position of constructing an individualized anesthetic plan of care that maximizes the
resistance to breast cancer cell proliferation.
Current literature suggests that the administration of VAA to breast cancer patients
undergoing breast cancer surgery may be associated with cancer recurrence and metastasis
through varying mechanisms that may potentiate the spread of cancerous cells, compared with
total intravenous anesthesia (TIVA). 3, 7-13 Although many high-level studies have demonstrated
the direct and indirect benefits of utilizing TIVA to reduce the prevalence of cancer recurrence
and metastasis in patients who underwent surgical interventions for breast malignancy, the
standardization of a TIVA-based anesthetic approach for the aforementioned patient population
to mitigate the risk of anesthesia-associated recurrence has not been established.3, 7-13 Since the
standardization of anesthetic management for this vulnerable patient population has yet to be
established, it is critical for anesthesia providers to familiarize themselves with current clinical
findings and tailor the anesthetic approach to optimize this patient population and provide a
favorable long-term outcome based on available empirical evidence.14
The primary goal of this Quality Improvement Project is to enhance the knowledge of
anesthesia providers regarding the correlation between TIVA and reduced breast cancer
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recurrence and metastasis compared with VAA via a comprehensive educational module to
initiate a paradigm shift in the anesthetic management of surgical patients with breast cancer
presenting for surgery. The objective of the development of a TIVA-based anesthetic protocol
for patients with breast malignancy presenting for breast surgery is to reevaluate current
practices and substitute a standardized approach that is based on empirical evidence to achieve
optimal recurrence and metastasis-free breast cancer patient outcomes. The implementation of a
TIVA-based anesthetic technique in the breast cancer patient population may be paramount to
anesthetic practice, as the choice of anesthetic may influence the long-term quality of life and
survival for breast cancer patients post-surgical intervention.7
VI. Goals and Outcomes
The acronym SMART was utilized to direct the development of the goal objectives for
this educational module. The SMART model articulates that objectives must be specific,
measurable, achievable, realistic, and time-limited; thus, ensuring the project will advance
toward the ultimate goal when completed.23-24
Specific
Anesthesia providers will have a standardized, evidence-based TIVA anesthetic
management protocol to mitigate the risk of anesthesia-associated breast cancer recurrence and
metastasis in patients with breast cancer presenting for surgical intervention.
Measurable
The efficacy of the TIVA anesthetic management protocol will be evaluated via the
analysis of a questionnaire that will be provided to the recipients before and after the delivery of
the educational intervention. Outcomes will be calculated through the evaluation of the
anesthesia providers’ knowledge and comprehension of the physiologic causes of breast cancer
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recurrence and metastasis secondary to surgical and anesthetic conditions; consequences of VAA
and TIVA anesthetic on immunologic function; long-term consequences of VAA and TIVA on
breast cancer outcomes; and the optimal multi-modal anesthetic plan of care for the breast cancer
patient population based on current evidence-based research. Qualtrics® software will be utilized
to generate surveys, analyze and synthesize the data, and yield results.
Achievable
The surgeons and anesthesia providers will collaborate to ensure that the anesthetic plan
is tailored to optimize each individual patient, while maintaining the integrity of a TIVA-based
anesthetic delivery to reduce the risk of breast cancer recurrence and metastasis secondary to
anesthetic technique in breast cancer patients undergoing breast surgery. Additionally, the patient
will be an active participant with a complete understanding of the interventions and steps taken
to provide the best possible long-term breast cancer-free outcome.
Realistic
Anesthesia providers will be educated on the recommended TIVA-based anesthetic
approach for breast cancer patients undergoing surgical intervention by the leader of this
educational initiative.
Timely
The TIVA-based anesthetic protocol for breast cancer patients presenting for breast
surgical intervention will be completed and available to anesthesia providers to access within a
6-month time period. The outcome of this initiative is designated as follows: within a 6-month
timeframe, anesthesia providers will have access to an evidence-based TIVA-anesthetic
management protocol for breast cancer patients presenting for breast surgical intervention that
will reduce the risks of anesthetic-associated breast cancer recurrence and metastasis and
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ultimately serve as the foundation for anesthesia providers to optimize long-term breast cancerfree outcomes for this patient population.
VII. Program Structure
The development of the TIVA-based anesthetic protocol for breast cancer patients
presenting for breast surgical intervention will require a paradigm shift in attitude and knowledge
with the collaborative effort of all stakeholders. Zaccagnini and White23 emphasize that the
conduction of a comprehensive assessment is critical to identify foreseeable roadblocks to the
implementation of educational module and respective potential solutions, as well as, the
establishment of a direction for the project that corresponds with the values and relevance to the
stakeholders involved. The utilization of the strengths, weaknesses, opportunities, and threats
(SWOT) assessment tool, will aid in the identification of internal and external characteristics that
serve as supportive or detrimental qualities to the success and sustainability of the educational
protocol implementation.23-24
Strengths
Breast cancer is one of the most prevalent variations of malignancy among women in the
US and has resulted in a paralleled influx of patients with breast malignancy undergoing surgical
intervention; thus, anesthesia providers are required to develop an anesthetic plan of care that is
optimal for breast cancer patients.1-2,22 Currently, there is no standardized anesthetic plan of care
for breast cancer patients presenting for breast surgery; however, research has associated TIVAbased anesthetic with favorable long-term patient outcomes evidenced by reduced breast cancer
recurrence and metastasis rates compared to patients that received VAA-based anesthesia.3, 7-13 It
is anticipated that a foundational strength of the development and successful implementation of a
TIVA-based anesthetic protocol for breast cancer patients undergoing surgical intervention is its
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congruence with each pillar of the organization’s mission and values: research, teaching, and
high-quality care. The organization of interest accentuates the significance of keeping abreast
current research to ensure a continuum of learning across disciplines in order to provide holistic,
optimal patient-centered care that is supported by evidence-based research and best practice
recommendations.
Developing and implementing a TIVA-based anesthetic management educational module
to guide the surgeon and anesthesia provider to work collectively to ensure that patients with
breast malignancy presenting for surgical intervention will have a reduced risk of breast cancer
recurrence and metastasis secondary to anesthesia technique; and ultimately, an optimal longterm outcome, aligns with the organization’s commitment to provide high-quality patient care
that fosters lifelong health and healing. Respectively, the goal of the educational module will be
to provide anesthesia providers with the knowledge necessary to tailor a TIVA-based anesthetic
plan of care that optimizes the long-term outcomes of breast cancer patients presenting for breast
surgery; thus, mitigating anesthesia-associated causes of recurrence and metastasis. Additionally,
it is important to note that the surgeons are equally committed to achieving the best possible
long-term outcomes for their patients and working together with the anesthesia provider to
ensure adequate surgical conditions are achieved with meticulous anesthetic management via
immunologic supportive methods.
Weaknesses
Zaccagnini & White23 define weaknesses as identified areas for improvement and might
include the performance of the organization or unit, perceived weak areas according to the
patients, and the availability, or potential, of resources to overcome the weaknesses. Parallel to
current literature, an internal problem observed is the existing attitude amongst several
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anesthesia providers regarding the perceived ease and efficiency of VAA-based anesthetic
compared to the preparation and administration of a TIVA-based approach.25 Lim et al25
articulate that anesthesia providers associate TIVA-based anesthesia with a longer set-up time,
increased risk for equipment failure and subsequent medical errors, and complicated anesthetic
management compared to the administration and titration of inhalational agents; however,
knowledge deficits regarding the aforementioned perceptions and concerns can be alleviated
with educational modules and training.
Additional weakness identified in the organization of interest include the different
methodology regarding the anesthetic care amongst anesthesiologists and nurse anesthetists, as
well as, the surgeons. For example, while a nurse anesthetist may advocate to proceed with a
combined regional anesthetic technique and TIVA-based approach, the anesthesiologist and
surgeon may settle for general anesthesia because the surgeon plans to administer local
anesthesia intra-operatively; thus, the competing modes of anesthetic and analgesic management
may result in inconsistency in patient management and subsequent barriers to successful
implementation of a standardized anesthetic protocol. The benefits of a TIVA-based anesthetic
with or without additional adjuvants must be considered and accepted by each stakeholder to
ensure the successful initiation of a practice and culture change related to the anesthetic care of
breast cancer patients presenting for breast surgery.
Opportunities
The implementation of a TIVA-based anesthetic management protocol for breast cancer
patients presenting for surgery provides an opportunity for anesthesia providers to be leaders at
the forefront of breast cancer surgical patient management to utilize the best empirical evidence
and reduce the potential for breast cancer reoccurrence and metastasis through anesthetic
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delivery. Anesthesia providers will be integral to the promotion of long-term cancer free
outcomes of this patient population and potentially initiate transitional change to anesthetic
practice that impacts the anesthetic approach for breast cancer patients, as well as, patients with
other known malignancies presenting for surgical intervention.
The initiation of a TIVA-based anesthetic protocol also provides an opportunity for the
anesthesia provider and surgeon to work collectively in the continuous reassessment and
evaluation for on-going improvement, while deepening the provider-patient rapport and
relationship. The collaborative efforts of the stakeholders to tailor an anesthetic that supports the
surgical plan of care to optimize the patient for surgery, as well as, the patients’ long-term breast
cancer outcome strengthens the relationship between disciplines and cultivates an environment
conducive to best-practice advancements. The anesthesia chief and anesthesia clinical
coordinator will be responsible for the approval of the program and select champions within the
department to lead the implemented practice change. The elected champions will provide an
educational module and determine the competency via meetings and observation. The anesthesia
providers will be responsible for development of a TIVA-based anesthetic plan of care based on
each individual patient with breast cancer presenting for breast cancer surgery. Lastly, the
surgeons will be expected to communicate their needs and plan with the anesthesia provider
through all stages of the operative period to ensure that the patient receives the anesthesia that is
both conducive to the surgical conditions and favorable long-term breast cancer outcomes.
Threats
The standardization of evidence-based practice has been universally recognized as a keydriver of high-quality patient care and optimal outcomes; however, barriers, or threats, to
implementation of evidence-based practice or quality improvement initiatives persist.26 Threats,
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which include obstacles to successful project implementation and sustainability, should be
evaluated to provide the project leader with a sense of direction and plan for the project’s best
chance for success.23-24 Interference with the programs’ ability to achieve its objectives may
include the anesthesia providers’ negative feelings toward the adoption of a standardized
anesthetic technique, which may be perceived as an infringement on their anesthetic “art” or
individuality. Lim et al25 found that anesthesia providers perceive TIVA-based anesthesia to be a
more time-consuming anesthetic approach involving a longer set-up time and requiring more
complicated titration. The researchers also discovered that despite the existing evidence that
TIVA-based anesthetic reduces the risk of breast cancer recurrence and metastasis compared to
VAA, anesthesia providers are reluctant and resistive to the adoption of a standardized TIVAbased anesthetic protocol, for it may jeopardize their anesthetic freedom and autonomy regarding
the anesthetic management of their patients.25 Ost et al26 identify that a major barrier to the
implementation of evidence-based practice or quality improvement initiatives is the readiness, or
preparedness, and culture of the staff.26 Ost et al26 stress that stakeholders must be willing and
ready to participate in projects aimed to institute change; this will eliminate inconsistency and
create an supportive environment conducive to a successful quality improvement initiative; thus,
it is critical for anesthesia providers to develop an understanding and appreciation of the impact
of the their anesthetic management on the long-term breast cancer outcomes of this patient
population to become active participants dedicated to the suggested transition to practice,
eliminate existing practice gaps, and ensure project success.23-24
Organizational Factors
The implementation of the TIVA-based anesthetic protocol for breast cancer patients
presenting for breast surgery will be conducted via a collaborative effort amongst disciplines.
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First, the author will determine the steps necessary to develop a TIVA-based anesthetic protocol.
A flowchart will be developed to provide visualization of the process steps, as well as, options
for anesthetic drug selection to individualize the anesthetic plan for each patient. Each patient
will have a form that the anesthesia provider can utilize to document the anesthetic plan and
selected drugs to facilitate analysis of the data in follow-up periods proceeding surgery to
correlate with recurrence and metastasis rates. Additionally, anesthesia providers will receive an
identical questionnaire and test before and after receipt of an educational module via Zoom
PowerPoint presentation to ascertain existing knowledge deficits and gauge understanding of the
implications of anesthetic administration and breast cancer outcomes; the results will be
compared to determine the success of the educational module pre- and post- implementation. In
the evaluation phase, the post-implementation surveys, as well as, the educational module posttest will be compared to the educational module pre-test to assess an improvement in knowledge
and attitude regarding the impact, feasibility, and efficacy of a TIVA-based anesthetic approach
in breast cancer patient undergoing surgical intervention. The stakeholders will be responsible
for a summary detailing the core findings resulted from their evaluation of the protocol and must
include: a concise description of the protocol, purpose statement, applied interventions, methods
utilized for data collection and analysis, background history surrounding the clinical issue, tools
utilized to collect and analyze data, pertinent results and conclusions, unanticipated and
unexpected outcomes, identified design flaws, and protocol improvement recommendations.
VIII. Conceptual Underpinning and Theoretical Framework
Middle range theories provide a foundation for healthcare professionals to seek an
understanding of their patients and their health complications from which appropriate
interventions are derived; thus, allowing healthcare professionals to provide a higher quality of
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care while simultaneously elevating the professional’s standards, accountability, and
autonomy.23,27 Peterson & Bredow27 emphasize that middle-range theories are less abstract and
more exact for practice implementation as the scope of the study is focused within the
parameters of a narrowed spectrum; therefore, a middle-range theory will be utilized to guide
this process. Kurt Lewin’s Change Theory models how groups process change and involves three
phases: unfreezing, change, and freezing.23 The change theory suggests that successful
implementation of change involves the preparation of those undergoing change via the
“unfreezing” of their current view of the issue, followed by the application of the change, and
“freezing” the new process into place.23 The application of the Change Theory is essential to
overcome the identified weaknesses and threats of the organization of interest surrounding the
existing anesthesia providers’ perception and attitude regarding standardized anesthetic
management and TIVA-based anesthetic administration. As the Change Theory suggests,
“unfreezing” current attitudes and beliefs facilitates an environment that is receptive to change
and the sustainability of the implemented change to practice will be favorable.
IX. Methodology
To successfully achieve the overall goal of this educational intervention, a series of steps
will be executed following the dissemination of the intervention to a specific group of
participants. The series of actions involving the target group will be detailed in the following
sections. Each of the following methodology sections are critical to the determination of the
educational module outcomes , as well as, the overall impact of anesthesia provider role in
reducing breast cancer recurrence and metastasis secondary to anesthetic mode of delivery to
breast cancer patients undergoing surgical intervention.
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Settings and Participants
The study will take place at Mount Sinai Medical Center (MSMC) located in Miami
Beach, Florida, which is a private hospital. The primary study participants will include
anesthesia providers of Miami Beach Anesthesia Associates (MBAA) and will range from
physicians to advanced practice nurses in the anesthesia profession. The participants will be
recruited voluntarily via an anonymous link distributed from an email within Qualtrics. If the
recruit consents to participate in the educational intervention, an anonymous link will redirect the
participant to a pre-educational module survey, followed by a video educational module, and a
post-educational module survey. The educational module was distributed to a total of 29
individuals; it is anticipated that the sample size will include approximately 5-10 participants.
Description of Approach and Educational Module Procedures
The primary objective of this proposed study is to distribute an online educational
intervention to anesthesia providers that emphasizes the implications of administering a TIVAbased anesthetic to patients with breast malignancy presenting for surgical intervention to
mitigate the risk of breast cancer recurrence and metastasis secondary to anesthetic delivery. The
initial phase of the project will involve an online pre-educational module assessment to ascertain
the participants’ baseline knowledge regarding the effects of anesthetic delivery on breast cancer
recurrence and metastasis, the effects of anesthetics on cytotoxic physiology, and the best mode
of anesthetic delivery to reduce the risk of breast cancer recurrence and metastasis in breast
cancer patients presenting for breast cancer surgery. The pre-educational module assessment will
also serve as a gauge to assess the anesthesia providers’ attitude regarding the adoption of a
TIVA-based approach for the anesthetic management of patients with breast malignancy
undergoing surgical intervention. The existing knowledge of the participating anesthesia
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providers in the selected clinical setting will be distinguished utilizing this preassessment tool;
thus, providing a baseline for comparison to the post-educational module assessment and allow
the researchers to evaluate the impact of the educational intervention on the improved knowledge
and attitude of anesthesia providers regarding the anesthetic management of breast cancer
patients presenting for breast cancer surgery.
Following a pre-educational module test, the participants will be directed to a 10-15
Voiceover PowerPoint presentation (VPP) that discusses the implications of anesthetic delivery
on breast cancer recurrence and metastasis in breast cancer patients presenting for surgical
intervention. The primary learning objective of the educational module will underscore the
detrimental effects and mechanism of action (MOA) of VAA on breast cancer recurrence and
metastasis via cytotoxic effects, compared to the benefits and MOA of TIVA on the mitigation of
breast cancer recurrence and metastasis via immunologic protectant effects. In order to eliminate
the existing research-to-clinical practice gap regarding the optimal anesthetic management of this
patient population, it is essential for anesthesia providers to acquire a keen awareness and
thorough comprehension of the magnitude of anesthetic management on the long-term outcomes
of patients with breast malignancy undergoing surgical intervention for treatment.25 The
provision of the VPP will inform anesthesia providers of the significance of utilizing a TIVAbased anesthetic for breast cancer patients presenting for breast cancer surgery to reduce the risk
of breast cancer recurrence and metastasis; thus, promoting favorable long-term outcomes and an
improved quality of life for this patient population. The research supports the need for an
educational intervention with comprehensive content regarding the impact of anesthetic delivery
on breast cancer recurrence and metastasis in breast cancer patients presenting for breast cancer
surgery.
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The final phase of the project will include an online post-educational module assessment
that serves to evaluate the knowledge gained by the anesthesia provider after successful
completion of the educational module. Additionally, the post-educational module test will assess
the aptitude for anesthesia provider support regarding a standardized TIVA approach for the
anesthetic management of the aforementioned patient population and help researchers determine
the next steps required to navigate a standardized anesthetic practice change to optimize the
long-term outcomes in the breast cancer surgical population. The pre-/post-test comparison will
provide pertinent data regarding the efficiency of the online educational intervention and
promote the adoption of a TIVA-based approach for the anesthetic management of breast cancer
patients undergoing breast cancer surgery.
Protection of Human Subjects
For this project, the recruitment population will include anesthesia providers who
administer anesthetic care to patients at MSMC including anesthesiologists and certified
registered nurse anesthetists (CRNAs). This population is significant due to their direct role in
the development of an anesthetic plan of care and the administration of anesthesia to patients
undergoing breast cancer surgery; thus, anesthesia providers will benefit from increased
knowledge regarding the optimal anesthetic mode of delivery to mitigate the risk of anesthesiaassociated breast cancer recurrence and metastasis and promote the best possible outcomes for
the breast cancer surgical population. Recruitment activities will be conducted via email
invitation through Qualtrics to all anesthesia providers of MSMC, which will provide an
anonymous link to the pre-educational module assessment that requires their voluntary consent
to participate. There will be no penalty should any participant elect to withdraw from the
educational intervention. There are no perceived risks associated with this project; however,
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elective participation requires 15-20 minutes of the anesthesia providers’ time to complete the
educational intervention phases to their entirety.
Data Collection
The primary tools utilized to determine the efficacy of this educational intervention
include a pre- and post-educational module assessment. The tests will be identical and conducted
in an anonymous survey format on Qualtrics; thus, comparison of the results from the pre- and
post-tests will elucidate if an improvement to the participants’ knowledge and attitude regarding
the administration of a TIVA-based anesthetic to reduce breast cancer recurrence and metastasis
to patients presenting for breast cancer surgery has occurred. The survey will consist of 12
questions that concentrate on the comprehension of anesthesia-associated breast cancer
recurrence and metastasis; the MOA of anesthetic agents on cytotoxic physiology; and the
optimal anesthetic delivery to optimize long-term outcomes in breast cancer patients undergoing
breast cancer surgical intervention. Additionally, the questions will assess the participants’
willingness to adopt the selection of a TIVA anesthetic for the management of the target patient
population.
The pre-test will allow the researchers to gauge anesthesia provider interest in the
educational intervention and existing baseline knowledge of the topic, while the post-test will
evaluate knowledge gain and the participants’ aptitude for applying this new knowledge to their
clinical practice. The reliability and validity of this data collection method will be measured
relative to the intervention and its overall impact on anesthesia providers. Confidentiality of the
participants and the data collected will be maintained and no subject identifiers will be recorded
throughout any component of this project.
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Data Management and Analysis Plan
The DNP student will be co-investigator of this project and responsible for dissemination
of the survey. The Qualtrics Stat-IQ software will be utilized to generate data based on the
responses submitted by the participants on the pre- and post-assessment and facilitate the
investigators’ ability decipher if an improvement to anesthesia provider knowledge and attitude
has occurred. The responses to each question will be recorded and measured to evaluate the
knowledge base before and after the educational intervention, in addition to, the identification of
aptitude adjustment following the completion of the module. The confidentiality of each
participant will be maintained, and all recorded responses will be anonymous without any
personal identifiers to preserve the unbiased integrity of the results collected from the pre- and
post-test data collection tools. The investigators anticipate that statistical analysis of the study
results will reflect the effectiveness of the educational module regarding the improvement of
anesthesia provider knowledge and attitude regarding the administration of a TIVA-based
anesthetic to prevent anesthesia-associated breast cancer recurrence and metastasis in breast
cancer patients presenting for breast cancer surgery. The data collected in this study is classified
and will be stored and secured by the co-investigator on a password-protected laptop computer.
X. Results
Pre-Test Demographics
The educational module pre-test demographics are outlined below in Table 1. It is
important to note that the post-test demographics are identical to the pre-test demographics; an
anonymous link redirected the participant to the post-test for completion following the
educational intervention VPP.
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Table 1
Pre-Test Participant Demographics
Demographic
Total Participants
Gender
Male
Female
Age (Free Response)
20-29
30-39
40-49
No Response
Ethnicity
Caucasian
Hispanic
Asian
Position/Title (Free Response)
CRNA
No Response
Level of Education
Doctorate
Experience as an Anesthesia Provider
5-10 years
2-5 years
1-2 years

n (%)
5 (100.00%)
1 (20.00%)
4 (80.00%)
1 (20.00%)
2 (40.00%)
1 (20.00%)
1 (20.00%)
3 (60.00%)
1 (20.00%)
1 (20.00%)
4 (80.00%)
1 (20.00%)
5 (100.00%)
1 (20.00%)
1 (20.00%)
3 (60.00%)

There were 5 participants (n= 5) in this study. The majority of participants were female
(n= 4, 80.00%), compared to male (n=1, 20.00%). Participants were able to enter a free response
to report their age; however, for the purpose of data analysis are divided according to decade:
age 20-29 (n=1, 20.00%), age 30-39 (n=2, 40.00%), age 40-49 (n=1, 20.00%), and one
participant omitted their response (n=1, 20.00%). Ethnicities of the participants in this study
varied: Asian (n=1, 20.00%), Caucasian (n=3, 60.00%), and Hispanic (n=1, 20.00%). CRNAs
represented the majority of participants (n=4, 80.00%); one participant omitted their response
(n=1, 20.00%). All 5 of the participants reported a doctorate level of education (n=5, 100.00%).
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Lastly, the representatives were questioned about their years of experience in the field, which
demonstrated the following: 1-2 years (n=3, 60.00%), 2-5 years (n=1, 20.00%), and 5-10 years
(n=1, 20.00%).
Pre-Test Knowledge of Breast Cancer Recurrence Secondary to Anesthetic Delivery
This section contains questions that assess the participants’ knowledge of the anesthetic
effects on breast cancer recurrence and metastasis. The majority of participants (60.00%) were
aware that VAA-based anesthesia increases the risk of breast cancer recurrence and metastasis
rates in breast cancer patients presenting for surgical intervention; however, one participant
(20.00%) elected that both TIVA and VAA-based anesthesia have been associated with
increased risk of breast cancer recurrence and metastasis. Alternately, one participant (20.00%)
selected that neither TIVA or VAA-based anesthesia have implications on breast cancer
recurrence and metastasis.
The second question within this category examined the participants’ knowledge of the
VAA association to increased pro-cancer markers in the miRNA of rats compared to the
anesthetic agents utilized in a TIVA-based anesthetic. The majority of surveyors identified that
VAA are linked to increased pro-cancer markers in the MiRNA of rats (80.00%), while one
participant lacked knowledge of this topic (20.00%). Only 2 out of 5 participants (40.00%)
recognized that breast cancer recurrence and metastasis secondary to surgical intervention is a
result of the impairment of immunological function by VAA during the perioperative period,
while 2 out of 5 surveyors (40.00%) believed breast cancer recurrence and metastasis secondary
to surgical intervention was multifactorial involving VAA and inadequate margins by the
surgeon. One participant (20.00%) believed the result of breast cancer recurrence and metastasis
secondary to surgical intervention was only attributed to inadequate margins by the surgeon.

60
Lastly, the participants were least versed on the overall implications of the mode of
anesthetic delivery on breast cancer recurrence and metastasis. Most surveyors (60.00%) selected
that it was true that anesthetic selection only posed a minimal risk for breast cancer recurrence
and metastasis in breast cancer patients undergoing surgical intervention; however, 2 out of 5
participants (40.00%) identified the magnitude of anesthetic selection on long-term breast cancer
outcomes.
Pre-Test Knowledge of Mechanism of Action of Anesthetics on Cytotoxic Physiology
This series of questions serves to elucidate the anesthesia providers’ knowledge of
anesthetic agent effects on cytotoxic and immunologic function in the perioperative period. The
majority of participating anesthesia providers (80.00%) were aware that anesthetic agents may
impair and/or support immunologic function, while 1 out of the 5 anesthesia providers (20.00%)
answered that the aforementioned statement was false. The next two questions required the
participants to select more than one answer; however, 2 out of 5 participants only selected one
option. For the aforementioned reason, it is significant to note that only the selection of both
correct answer choices selected by the surveyor were deemed correct.
Only 2 out of 5 participants (40.00%) accurately identified NK-1 cells and MiRNA as the
primary culprits for the cytotoxic effects that contribute to the prevention of cancer cell
migration and proliferation in the perioperative period. As previously stated, 2 out of 5 (40.00%)
participants failed to select two answer choices as directed in the question and 1 out 5 (20.00%)
only selected one correct option. All of the participating anesthesia providers demonstrated a
knowledge deficit regarding the NK-1 cell immunological functions, reflected by the 0 out of 5
participants (0.00%) that answered the question correctly; however, 2 out of 5 (20.00%) of
participants failed to select 2 answer choices as instructed in the question.
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Only 1 out of 5 (20.00%) participating anesthesia providers were aware of the impact of
VAA on overall immunological function in the perioperative period including the proliferation
and migration of cancerous cells and the direct impairment of the cytotoxic effects of NK-1 cells;
thus, leading to breast cancer recurrence and metastasis. An obvious knowledge deficit regarding
the MOA of anesthetic agents on cytotoxic physiology exists among the participating anesthesia
providers in this study, as evidenced by the recorded responses to the pre-educational module
assessment questions in this category.
Pre-Test Knowledge of TIVA to Prevent Breast Cancer Recurrence and Metastasis
There was a notable knowledge deficit amongst participants (0.00%) regarding TIVA as
the optimal anesthetic approach to prevent breast cancer recurrence and metastasis relative to the
immunologic pathophysiology and MOA; however, 2 out of 5 participants (40.00%) failed to
select 3 answer choices as directed in the question. Most surveyors (60.00%) were able to
distinguish that a combined TIVA-based anesthetic with regional and multimodal adjuvants is
the best anesthetic method to reduce the risk of breast cancer recurrence and metastasis. The
majority of participants (60.00%) knew that breast cancer patients that underwent breast cancer
surgery and received TIVA had reduced 1- and 5-year breast cancer recurrence and metastasis
rates, compared to those that received VAA.
Pre-Test Aptitude for Standardized TIVA for Breast Cancer Patients Undergoing Surgery
There were varying responses regarding the anesthesia providers’ attitude and willingness
toward the administration of TIVA for the anesthetic management of breast cancer patients
presenting for surgical intervention. There were equal responses (40.00%) where participating
anesthesia providers would either most likely use or somewhat likely use TIVA in the anesthetic
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management of breast cancer patients undergoing breast cancer surgery. Only one respondent
reported (20.00%) that they are somewhat unlikely to use.
Post-Test Knowledge of Breast Cancer Recurrence Secondary to Anesthetic Delivery
Post-test knowledge of breast cancer recurrence secondary to anesthetic delivery
incorporates data regarding the participants’ knowledge of the anesthetic effects on breast cancer
recurrence and metastasis following the completion of the educational intervention. All of the
surveyors (100.00%) successfully identified that VAA-based anesthesia increases the risk of
breast cancer recurrence and metastasis rates in breast cancer patients undergoing surgical
intervention. Equally favorable results demonstrated a thorough comprehension that VAA are
implicated in the increased pro-cancer markers in the MiRNA of rats, compared to TIVA
(100.00%). There was no improvement among participants regarding the knowledge of breast
cancer recurrence and metastasis causes during surgical intervention (40.00%); surveyors
attributed inadequate margins by the surgeon as an additional cause of breast cancer recurrence
and metastasis among the breast cancer patients. Finally, most participants (60.00%)
acknowledged that there is a great risk of breast cancer recurrence and metastasis associated with
the mode of anesthetic delivery and the selection of anesthetic agents utilized in the anesthetic
management of patients with breast cancer that undergo surgical intervention. Table 2 illustrates
the differences in responses from the pre- and post-tests, as well as, the improvement percentage.
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Table 2
Difference in Pre- and Post-Test (Knowledge of Breast Cancer Recurrence Secondary to
Anesthetic Delivery)
True Responses
Which type of anesthesia increases the risk of breast cancer
recurrence and metastasis rates in breast cancer patients
presenting for surgical intervention?
Volatile anesthetic agents (VAA) are linked to increased
pro-cancer markers in the miRNA of rats compared to total
intravenous agents (TIVA), such as propofol; true or false?
Breast cancer recurrence and metastasis secondary to
surgical intervention is:
Patients with breast cancer that undergo surgical
intervention are at a MINIMAL risk for breast recurrence
and metastasis secondary to the mode of anesthetic delivery
and the selection of anesthetic agents; true or false?

Pre-test Post-test Difference
60.00% 100.00% 40.00%
.
80.00%

100.00% 20.00%

40.00%

40.00%

0.00%

40.00%

60.00%

20.00%

In Table 2 shown above, there was an overall increase in anesthesia provider knowledge
of breast cancer recurrence and metastasis secondary to anesthetic delivery. There was notable
improvement (40.00% increase) in the participant knowledge of VAA implications on increased
risk for breast cancer recurrence and metastasis rates in breast cancer surgical patients. There
was also a knowledge improvement regarding VAA effects on pro-cancer markers in the
MiRNA of rats (20.00%) and the severe impact of the mode of anesthetic delivery and selection
of anesthetic agents on breast cancer recurrence and metastasis (20.00%); however, participants
continue to report inadequate margins as the culprit for increased breast cancer recurrence and
metastasis rates in breast cancer patients undergoing surgical intervention (reflected by a 0.00%
increase).
Post-Test Knowledge of Mechanism of Action of Anesthetics on Cytotoxic Physiology
Post-test knowledge of the mechanism of action of anesthetics on cytotoxic physiology
improved the anesthesia providers’ knowledge of anesthetic agent effects on cytotoxic and
immunologic function in the perioperative period following the completion of the educational
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module. While only a 20.00% increase, all of the participating anesthesia providers (100.00%)
knew that anesthetic agents may impair and/or support immunological function. There was no
improvement of knowledge demonstrated between the pre- and post-test (40.00%) regarding the
fact that NK-1 cells and MiRNA cytotoxic cells responsible for the prevention of cancer cell
migration and proliferation in the peri-operative period; however, 2 out of 5 participants
(40.00%) failed to select 2 answer choices and instructed in the question. A knowledge increase
(40.00%) regarding the immunological function and MOA of NK-1 cells in the peri-operative
period is acknowledged, as none of the anesthesia providers answered this question correctly in
the pre-test. Lastly, the greatest knowledge improvement in this series includes the detrimental
effects and MOA of
VAA on immunological function and is evidenced by a 60.00% difference.
Table 3 outlines the differences in responses from the pre- and post-tests, as well as, the
improvement percentage for the knowledge of anesthesia providers in this question theme.
Table 3
True Responses
Pre-test Post-test Difference
Anesthetic agents may impair and/or support immunologic
80.00% 100.00% 20.00%
function; true or false?
.
Which of the following are primarily credited for the
40.00% 40.00% 0.00%
cytotoxic effects responsible for the prevention of cancer
cell migration and proliferation in the perioperative period?
(Select 2).
Natural Killer Cells (NK-1) are responsible for which of the 0.00%
40.00% 40.00%
following immunological functions in the peri-operative
period? (Select 2)
Which of the following accurately describes the impact of
20.00% 80.00% 60.00%
volatile anesthetic agents (VAA) on immunological
function?
Difference in Pre- and Post-Test (Knowledge of Mechanism of Action of Anesthetics on
Cytotoxic Physiology)
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It is acknowledged that there was a knowledge improvement following completion of the
educational module, except for 1 out of 4 questions. This suggests that the educational module
successfully increased the anesthesia providers’ knowledge of anesthetics on cytotoxic
physiology.
Post-Test Knowledge of TIVA to Prevent Breast Cancer Recurrence and Metastasis
Post-test knowledge of TIVA to prevent breast cancer recurrence and metastasis details
the increased knowledge amongst participating anesthesia providers that TIVA is the optimal
mode of anesthetic to prevent breast cancer recurrence and metastasis in patients with breast
malignancy presenting for breast cancer surgery. There was a congruent increase of anesthesia
provider knowledge (40.00%) for each question within this category. It is important to note that
all 5 (100.00%) of participants were able to correctly identify that a combined TIVA-based
anesthetic with regional and multimodal adjuvants is the optimal anesthetic approach for the
aforementioned patient population following the completion of the educational module.
Additionally, 100.00% of surveyors were able to report that breast cancer patients that underwent
breast cancer surgery and received TIVA had reduced 1- and 5-year breast cancer recurrence and
metastasis rates, compared to those that received VAA. The comparison of pre- and post-module
knowledge is demonstrated below in Table 4.
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Table 4

True Responses

Pre-test Post-test Difference

The mechanism of action and/or pathophysiology by which
0.00% 40.00% 40.00%
total intravenous anesthetic (TIVA) agents support
.
immunological function includes: (Select 3)
The best anesthetic method to REDUCE the risk of breast
60.00% 100.00% 40.00%
cancer recurrence and metastasis is:
Breast cancer patients that underwent breast cancer surgery 60.00% 100.00% 40.00%
and received a total intravenous anesthetic (TIVA) had
reduced 1- and 5-year breast cancer recurrence and
metastasis rates, compared to those that received volatile
anesthetic agents (VAA); true or false?
Difference in Pre- and Post-Test (Knowledge of TIVA to Prevent Breast Cancer Recurrence
and Metastasis)
Table 4 delineates an increase in anesthesia provider knowledge that a TIVA-based
anesthetic is the optimal mode of anesthetic delivery to prevent anesthesia-associated breast
cancer recurrence and metastasis in breast cancer patients undergoing breast cancer surgery.
Post-Test Aptitude for Standardized TIVA for Breast Cancer Patients Undergoing Surgery
The final section of the data collection analyzes the participants’ attitude toward the
adoption of a standardized TIVA-based anesthetic care of breast cancer patients presenting for
surgical intervention following the completion of the educational module. Although the
researchers of this study hoped that all participants of this study would opt to utilize a TIVAbased anesthetic due to the implications of VAA, only 4 out of 5 (80.00%) of participating
anesthesia providers stated that they would most likely use TIVA in the anesthetic management
of the aforementioned surgical patient population. There was an overall improvement of the
anesthesia provider attitude toward a TIVA-based anesthetic approach (40.00%) increase from
the pre- to post- educational module assessments, as reflected in Table 5.
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Table 5
Difference in Pre- and Post-Test (Aptitude for Standardized TIVA for Breast Cancer Patients
Undergoing Surgery)
True Responses
What is your attitude in utilizing total intravenous
anesthesia (TIVA) for the anesthetic management of breast
cancer patients presenting for surgical intervention?

Pre-test Post-test Difference
40.00% 80.00% 40.00%
.
….

Summary
Overall, the results reflect that there was a degree of improvement in correct answers
from the pre- to post-educational module assessment. There was an increase in knowledge and
attitude amongst the participating anesthesia providers following the completion of this
educational intervention.
XI. Discussion
Limitations
Limitations of this study include the small sample size (n= 5). This project was
disseminated to the anesthesia group at a large private hospital. A multi-center study that
incorporates additional anesthesia groups would have been ideal and likely strengthen the
validity of the study results. Time was an additional barrier to the study, as the candidates had
only two weeks to initiate and complete all phases of the educational module. The researchers
believe that a longer timeframe would have solicited greater participation from anesthesia
providers; thus, adding value to the project with a larger sample size. Lastly, the online delivery
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method of the project may have impacted the overall participation from anesthesia providers due
to the asynchronous format and a two-week deadline to complete the survey.
Future Implications for Advanced Practice Nursing
While many variations of malignancy fall under the looming cancer umbrella, breast
cancer is reportedly the most aggressive and prevalent origins of cancer and the primary cause of
cancer-related death among women in the US.1-2,22 As breast malignancy diagnoses continue to
climb, the requirement for the recommended treatment involving surgical intervention to
eradicate the cancerous tissue grows, respectively. Research suggests that the mortality
associated with breast cancer diagnosis is triggered by recurrence, or metastasis, that occurs after
resection of the primary tumor secondary to the circulation of tumor cells throughout the perioperative period and concurrent suppression of the patient’s immune system under surgical
conditions, particularly in relation to VAA delivery. 3, 7-13 Current evidence-based research has
illuminated the impactful role that anesthesia providers may have on the long-term outcomes of
patients with breast malignancy presenting for surgical intervention via the selection of a TIVAbased anesthetic approach.22
The high-level research studies included as the basis of this study echo the recurring
themes regarding the correlation between TIVA anesthesia and reduced breast cancer recurrence
and metastasis in the surgical breast cancer patient population with supporting evidence and
statistics; however, standardization of the anesthetic management of the target patient population
has yet to be established. Since the evidence-based research-to-clinical practice gap exists, it is
critical to inform anesthesia providers of the implications of anesthetic delivery in breast cancer
patients to overcome the knowledge deficit and initiate a cultural shift toward the adoption of a
TIVA-based anesthetic for patients with breast malignancy presenting for breast surgery. All
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eight of the studies included in research for this project emphasized the significance of anesthetic
technique in the management of the investigative patient population: the detrimental impact of
VAA on the immunologic response and cancer cell proliferation; the efficacy of TIVA in
suppressing the peri-operative stress response; and reduced breast cancer recurrence rates in
patients that received TIVA-based anesthetic compared to those that received VAA. The purpose
of this educational intervention was to unite the identified themes to facilitate a positive change
to anesthetic practice that optimizes the quality of life of patients with breast cancer presenting
for surgical intervention.
In summary, the evidence ascertained from the eight aforementioned studies solidified
the foundation for this quality improvement (QI) project, which serves as a catalyst to
standardize the adoption of a TIVA-based approach for the anesthetic management of patients
with breast malignancy presenting for surgical intervention. The author of this QI project aimed
to bridge the knowledge-to-clinical practice gap among anesthesia providers regarding the
optimal anesthetic management to reduce the risk of breast cancer recurrence and promote longterm survival in this vulnerable patient population. The outcomes of this educational intervention
are critical to the identification of the strategies required to enhance the anesthesia providers’
capacity to improve the quality of life and reduce the risk of life-altering implications with the
selection of their anesthetic approach in breast cancer patients.
It is evident that the administration of this educational module expounds the anesthesia
providers’ knowledge of anesthesia-associated breast cancer recurrence and metastasis in breast
cancer patients presenting for surgical intervention. Overall, the data demonstrates that the
educational intervention was efficacious in increasing the anesthesia providers’ knowledge and
propensity regarding the administration of a TIVA-based anesthetic to reduce breast cancer
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recurrence and metastasis in breast cancer patients undergoing breast cancer surgery. It is
prudent to present the success of this educational intervention with other clinical settings in an
attempt to initiate a paradigm shift in the anesthetic care of the breast cancer patient population
undergoing surgical intervention. Additional research that focuses on the best anesthetic
selection to optimize the breast cancer patient population, as well as, the dissemination of this
educational module to other clinical settings is recommended to substantiate our findings and
prompt a universal practice change.
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Appendix C
Proposed Method for Data Collection
Pre-Survey and Post-Survey

INTRODUCTION
The primary aim of this Quality Improvement Project is to enhance the knowledge of anesthesia
providers regarding the correlation between TIVA and reduced breast cancer recurrence and
metastasis compared with VAA via a comprehensive educational module to initiate a paradigm
shift in the anesthetic management of surgical patients with breast cancer presenting for surgery.
Please answer the question below to the best of your ability. The questions are either in multiple
choice or true/false format and are meant to measure knowledge and perceptions on anesthetic
selection for breast cancer patients presenting for surgical intervention and the effects of
anesthetics on breast cancer patient long-term outcomes.
I. DEMOGRAPHICS
1. Gender:
A. Male
B. Female
C. Prefer Not to Answer
2. Age: ______
3. Ethnicity:
A. Hispanic
B. Caucasian
C. African American
D. Asian
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E. Other
F. Prefer not to answer
4. Position/Title: _______________________
5. Level of Education
A. Certificate
B. Bachelors
C. Masters
D. Doctorate
E. Other
6. How many years have you been an anesthesia provider?
A. Over 10
B. 5-10 years
C. 2-5 years
D. 1-2 years
II. KNOWLEDGE ACCURACY
1. Which type of anesthesia increases the risk of breast cancer recurrence and metastasis
rates in breast cancer patients presenting for surgical intervention?
A. Total Intravenous Anesthesia (TIVA)
B. Volatile Anesthetic Agents (VAA)
C. Both A and B
D. Neither A nor B
2. Volatile anesthetic agents (VAA) are linked to increased pro-cancer markers in the
miRNA of rats compared to total intravenous agents (TIVA), such as propofol?

75
A. True
B. False
3. Anesthetic agents may impair and/or support immunologic function; true or false?
A. True
B. False
4. Which of the following are primarily credited for the cytotoxic effects responsible for the
prevention of cancer cell migration and proliferation in the perioperative period? (Select
2).
A. Natural Killer Cells (NK-1)
B. Neutrophils
C. T & B Lymphocytes
D. miRNA
5. Natural Killer Cells (NK-1) are responsible for which of the following immunological
functions in the peri-operative period? (Select 2)
A. Inhibition of adrenergic activation associated with surgical stress
B. Prevention of cancer cell migration and proliferation
C. Inhibition of cancer cell marker concentrations in the post-operative period
D. Prevention of cancer cell migration, but not proliferation
E. Prevention of cancer cell proliferation, but not migration
6. The mechanism of action and/or pathophysiology by which total intravenous anesthetic
(TIVA) agents support immunological function includes: (Select 3)
A. Increased natural killer (NK-1) cell response
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B. Increased cyclooxygenase-2 (COX-2) activity, thus increased production of the
foundational tumor-progression hormone, PGE2
C. Decreased cyclooxygenase-2 (COX-2) activity, thus decreased production of the
foundational tumor-progression hormone, PGE2
D. Suppression of malignant cell metastasis in vitro throughout the peri-operative
period
E. Suppression of malignant cell metastasis in vitro in the post-operative period
7. Breast cancer recurrence and metastasis secondary to surgical intervention is:
A. A result of inadequate margins surgically removed by the surgeon in the intraoperative period
B. Environmental exposures and lifestyle
C. The impairment of immunological function by inhalational agents (VAA) during
the perioperative period
D. A&C
8. The best anesthetic method to REDUCE the risk of breast cancer recurrence and
metastasis is:
A. TIVA anesthetic with 0.5 MAC of inhalational agents and non-opioid analgesics
B. Combined TIVA-based anesthetic with regional and other multi-modal adjuvants
C. Any mode of anesthetic is acceptable, as long as there are no contraindications
D. VAA maintained at 1.3 MAC
9. Which of the following accurately describes the impact of volatile anesthetic agents
(VAA) on immunological function?
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A. VAAs impair the cytotoxic effects of immunocompetent cells, such as natural
killer (NK-1) cells; thus, contributing to breast cancer cell migration
B. VAAs impair the cytotoxic effects of immunocompetent cells, such as natural
killer (NK-1) cells; thus, contributing to breast cancer cell proliferation
C. VAAs impair the cytotoxic effects of immunocompetent cells, such as natural
killer (NK-1) cells; thus, reducing the body’s resistance to cancer cell
implantation, resulting in recurrence and metastasis
D. All of the above
10. Patients with breast cancer that undergo surgical intervention are at a MINIMAL risk for
breast recurrence and metastasis secondary to the mode of anesthetic delivery and the
selection of anesthetic agents; true or false?
A. True
B. False
11. Breast cancer patients that underwent breast cancer surgery and received a total
intravenous anesthetic (TIVA) had reduced 1- and 5-year breast cancer recurrence and
metastasis rates, compared to those that received volatile anesthetic agents (VAA); true
or false?
A. True
B. False
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III. ATTITUDE TOWARD PRACTICE CHANGE
12. What is your attitude in utilizing total intravenous anesthesia (TIVA) for the anesthetic
management of breast cancer patients presenting for surgical intervention?
A. Will most likely use
B. Will somewhat likely use
C. Somewhat unlikely to use
D. Most unlikely to use
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Appendix D
Educational Module

7/2/22
Background

Quality Improvement Project Learning Goals

Total Intravenous Anesthesia to Reduce Metastasis
and Recurrence Rates in Patients Presenting for
Breast Cancer Surgery: An Educational Module

Breast cancer is the leading cause of cancer-related
death among women in the United States

Understand the evidence supporting the administration of Total Intravenous Anesthesia (TIVA) to
prevent breast cancer metastasis and recurrence, compared with Volatile Anesthetic Agents (VAA)
Understand the physiological impact of TIVA vs VAA on immunologic function in the breast cancer
patient undergoing surgical intervention

Research suggests that mortality associated with breast cancer
is directly related to metastasis triggered by suppression of the
body's immune response throughout the perioperative period
and during tumor resection

Identify the optimal anesthetic technique for breast cancer patients presenting for breast
cancer surgery
Although volatile anesthetic agents (VAA) based
anesthesia has been associated with breast cancer
recurrence, a standardized anesthetic plan of care for
radical mastectomy has not been established

Discuss the effects of the proposed anesthetic technique on clinical outcomes for breast cancer
patients undergoing surgical intervention

Kiersten A. de la Vega, BHS, BSN, RN, CCRN
Ann B. M iller, DNP, CRNA, APRN

Describe an educational algorithm for the selection of appropriate medications for breast cancer
patients undergoing breast cancer surgery

3

2

1

TIVA Anesthesia technique for patients undergoing radical
mastectomy may minimize suppression of the immune
response during the intra-operative period, thus play a major
role in long-term metastasis prevention

Scope of the Problem

TIVA vs Immunological Function, Recurrence, and
Metastasis Rates

Total Intravenous Anesthesia

Patients with breast malignancy that underwent surgical intervention are at risk for breast cancer recurrence and metastasis secondary
to anesthetic-related immunosuppression

TIVA vs
Immunological
Function

• To ta l In traven o u s A n e sth esia invo lve s a n an e sth e tic state ach ie ve d w ith
th e a d m in istratio n o f in trave n o u s an e sth etic age n ts
• Pre se rve s im m u n o lo gical fu nctio n in th e p eri-o p e rative p e riod
• N K-1 ce ll fun ctio n m a in tain s cyto tox ic effe cts
• Preve n ts m align a nt cell m igratio n an d p ro life ration , w h ich le ad s to
lo n g -te rm re cu rre n ce a n d m e tastasis
• Effe ctive ly in h ib its in cre a se s in ca n ce r ce ll m arke r con cen tratio n s in
th e p ost-o p e rative p e rio d
• A sso ciate d w ith 1-ye a r an d 5 -yea r re cu rre nce a n d m etasta sis-fre e rate s
statu s-p o st su rg ica l in te rve ntio n fo r b re a st ca n ce r, co m p a re d to p atie n ts
th at rece ived vo latile an e sth e tic a gen ts

According to the American Cancer Society, the estimated number of new invasive breast cancer diagnoses in women in the US is
approximately 281,550 in 2021
The incidence of breast cancer continues to climb steadily at a rate of 0.5% despite advancements in breast malignancy detection and
treatment
1 in 39 women, or 2.6%, die from breast cancer each year which mirrors the American Cancer Society’s estimated 43,600 incidences of
breast malignancy-associated deaths projected in 2021
Proliferation of malignant breast cells is associated with as low as a 28% survival rate.
Various anesthetic agents, such as VAA and opioids have been implicated in impairing immunologic function and contributing to cancer
metastasis via inhibition of the immunocompetent cells

S u p p o r ts N K -1 ce ll a n d
ly m p h o cy t e c y t o to x ic
e ff e c ts in t h e p e ri o p e ra tiv e p er io d

P ro p o fo l-b a s e d T IV A w ith
a m u ltim o d a l a n e s th e tic
d e liv e ry w a s a ss o c ia t ed
w ith th e m o s t o p tim a l
o u tco m e s

VAA vs Immunological Function, Recurrence, and
Metastasis Rates
VAA vs
Immunological
Function

• Volatile Ane sthetic Agents involve s a n ane sthetic state achieve d w ith the
adm inistratio n o f inha latio nal ane sthetic agents
• Im pairs im m unological function in the pe ri-ope rative perio d
• N K-1 cells lo se the ir cytotoxic effects
• Facilitate s m alig nant ce ll m igratio n a nd pro liferation, w hich le ads
incre ased risk o f lo ng-term recurre nce and m e tastasis
• Perm its increase s in cancer ce ll m arker concentrations in the po stope rative pe rio d
• A ssociate d w ith 1-year a nd 5-ye ar re curre nce and m etastasis status-post
surgical interve ntion for breast cancer, com pare d to patients that re ceived
TIVA a nesthetic

D o s e -d e p e n d e n t
im p a irm e n t

S u p p re s s e s N K -1 c e ll a n d
ly m p h o c y te c y to to x ic
f u n c tio n

VAA vs Breast
Cancer
Recurrence

A s so c ia t e d w it h 1 a n d 5 y e a r p o st -o p e r a t iv e

re cu r re n ce

p e rio d m e ta s ta s is

S ta tis ti ca lly s ig n ifica n t r e s u lts
a n d e v id e n c e s u p p o rts V A A
fa c ilita te s in c re a s es in c a n ce r
m a r k e r c o n c en t ra tio n s a ft e r
s u r g ic a l in te r v e n tio n in b r e a s t
c a n c e r p a tie n t s

A s so c ia te d w ith o v e r a ll
d e c r e a s e d b r e a s t c a n ce r

D ata Collection and
Quality
Im provem ent
Im plementation

TIVA-based
Anesthesia for
Breast Cancer
Surgical
Intervention
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Take Home Points

Mitigate suppression of the immune
system during the intra-operative period
to prevent cancer cell proliferation
Focused scope w ith
an identified need to
m itigate breast
cancer m etastasis in
patients undergoing
radical m astectomy

VAA inhibit NK cell
function, which
potentiates cancer cell
dissemination and
proliferation during the
peri-operative period

Prevent breast cancer recurrence

Decreased hospital length of stay in the
post-operative period and optimal
analgesia

No additional
training, staff, or
organizational
changes required to
im plem ent
proposed change to
practice

10

s u rv iv a l

s u rv iv a l ra te s

Anticipated Effects of the Quality
Improvement Project

Feasibility of Proposed Educational Intervention

Consistent patientcentered evidencebased anesthetic
care

A s s o cia te d w ith
in c r ea s e d b r e a s t ca n c e r

The standardization of TIVA-based anesthetic for the management of breast
cancer positive patients undergoing surgical intervention to reduce the risk
of breast cancer recurrence and metastasis and promote favorable longterm outcomes.
• Implementation of an educational module regarding the anesthetic
management of breast cancer patients presenting for surgical
intervention
• Bridge the knowledge-to-practice gap
• Serve as a catalyst to initiate change in anesthetic management
of breast cancer patients
• Reduce the risk of recurrence and metastasis secondary to
anesthetic administration

E v id e n ce su p p o rt s V A A b a se d a n e s th e s ia tis
lin k e d to lo n g -t e rm
b r e a s t c a n c e r m e ta s ta s is
a n d d e a th

8

Elim ination of delays
in evidence-topractice transition

E v id e n ce s u p p o r ts T IV A b a s ed a n e s th e s ia t o
o p tim iz e lo n g -t er m 5 year b reast can cer
r e cu rr e n ce p r e v e n t io n

Proposed Quality Improvement via Educational
Intervention

VAA vs Breast
Cancer
Metastasis

A s so c ia t ed w it h 1 a n d 5 y e ar bre ast c an ce r

P ro -ca n ce r e f fe c ts o n
m iR N A e x p r e s s io n in ra ts

7

o p e ra tiv e p e rio d s

r e c u rr e n c e

S ta tis tic a lly sig n ific a n t r es u lt s
a n d e v id e n c e s u p p o rts T IV A to
ef fe ct iv e ly in h ib it in cr e a s e s in
c a n ce r m a rk e r c o n c e n tr a tio n s
a ft e r su r g ic a l in te r v e n tio n

6

5
Volatile Anesthetic Agents

1

Lin k e d to m e t a s ta s is -fr e e
1 a n d 5 -y e a r p o st -

A s s o cia te d re d u c e d 1 a n d
5 -y ea r b r e a s t c a n c e r

A n ti-c a n c er e f fe ct s o n
m iR N A e x p re s s io n in r a t s

TIVA anesthetic coupled with a multi-modal approach has demonstrated preservation of immunocompetent cell function, which is
responsible for the resistance to cancer cell implantation, a well-documented precursor to cancer metastasis.

4

TIVA vs Breast
Cancer
Metastasis

TIVA vs Breast
Cancer
Recurrence

Consistency in anesthetic care

11

TIVA-based anesthetic
approach may evade
the concerns of
immunologic
suppression via
inhibition of natural
killer (NK) cells

TIVA proffers a higher
probability of favorable
long-term, recurrence
and metastasis-free
outcomes

TIVA vs VAAbased
A nesthesia for
B reast Cancer
Surgical
Intervention

VAA are strongly
associated w ith
breast cancer
recurrence and
m etastasis and
should be avoided

TIVA should be
considered as the
standardized
anesthetic
m anagem ent plan for
breast cancer patients
presenting for surgical
intervention
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